Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 3	OCT 19	BEILSTEIN updated with new compounds
NEWS 4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 5	NOV 19	WPIX enhanced with XML display format
NEWS 6	NOV 30	ICSD reloaded with enhancements
NEWS 7	DEC 04	LINPADOCDB now available on STN
NEWS 8	DEC 14	BEILSTEIN pricing structure to change
NEWS 9	DEC 17	USPATOLD added to additional database clusters
NEWS 10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 11	DEC 17	DGENE now includes more than 10 million sequences
NEWS 12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 16	JAN 02	STN pricing information for 2008 now available
NEWS 17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 19	JAN 28	MARPAT searching enhanced
NEWS 20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23	FEB 08	STN Express, Version 8.3, now available
NEWS 24	FEB 20	PCI now available as a replacement to DPCI
NEWS 25	FEB 25	IFIREF reloaded with enhancements
NEWS 26	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 27	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:26:01 ON 02 MAR 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:26:27 ON 02 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 FEB 2008 HIGHEST RN 1005981-96-3
DICTIONARY FILE UPDATES: 29 FEB 2008 HIGHEST RN 1005981-96-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10561417a.str





chain nodes :
10 11 12 13 14 15 16 17 18 20 22
ring nodes :
1 2 3 4 5 6 7 8
chain bonds :
1-18 2-16 2-17 4-22 6-14 6-15 7-12 7-13 8-10 8-11 18-20
ring bonds :
1-2 1-6 2-3 3-4 3-8 4-5 5-6 5-7 7-8
exact/norm bonds :
1-2 1-6 1-18 2-3 3-4 4-5 5-6 18-20
exact bonds :
2-16 2-17 3-8 4-22 5-7 6-14 6-15 7-8 7-12 7-13 8-10 8-11
isolated ring systems :
containing 1 :

G1:O,S,N

G2:C,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 10:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 20:Atom
22:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 12:26:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 942 TO ITERATE

100.0% PROCESSED 942 ITERATIONS 10 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 16999 TO 20681
PROJECTED ANSWERS: 11 TO 389

L2 10 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 12:26:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 18201 TO ITERATE

100.0% PROCESSED 18201 ITERATIONS 278 ANSWERS
SEARCH TIME: 00.00.01

L3 278 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 12:26:52 ON 02 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Mar 2008 VOL 148 ISS 10
FILE LAST UPDATED: 29 Feb 2008 (20080229/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 28 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1364459 CAPLUS
DOCUMENT NUMBER: 148:33707
TITLE: Fused bicycloheterocycle substituted azabicyclic alkane derivatives and their preparation, pharmaceutical compositions and use in the treatment of diseases
INVENTOR(S): Ji, Jianguo; Li, Tao; Lynch, Christopher L.; Gopalakrishnan, Murali
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 107pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007137030	A2	20071129	WO 2007-US68930	20070515
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2008045539	A1	20080221	US 2007-748527	20070515

PRIORITY APPLN. INFO.: US 2006-802195P P 20060519
OTHER SOURCE(S): MARPAT 148:33707
GI



I



II

AB The invention relates to fused bicycloheterocycle substituted azabicyclic alkane derivs. of formula I, compns. comprising such compds., and methods of treating conditions and disorders using such compds. and compns. Compds. of formula I wherein X is (CH2)1-3; A is N and N+O-; R is H, alkyl, cycloalkylalkyl, and arylalkyl; L is O, S, and NH and derivs.; Ar1

is 6-membered (hetero)aryl; Ar2 is bicyclic heteroaryl; and their pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, are claimed. Example compound endo-II•TFA was prepared by O-arylation of endo-tropine with 3,6-dichloropyridazine; the resulting endo-3-(6-chloropyridazin-3-yloxy)-8-methyl-8-azabicyclo[3.2.1]octane underwent cross-coupling with 5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-1H-indole to give endo-II•TFA. All the invention compds. were evaluated for nAChR binding affinity.

IT 959394-80-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of fused bicycloheterocycle substituted azabicyclic alkane derivs. useful in treatment and prevention of diseases)

RN 959394-80-0 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[[6-(1H-indol-5-yl)-3-pyridinyl]oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



IT 959157-91-6P 959157-95-0P 959157-96-1P
959158-57-7P 959158-58-8P 959394-73-1P
959394-74-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of fused bicycloheterocycle substituted azabicyclic alkane derivs. useful in treatment and prevention of diseases)

RN 959157-91-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[[6-(1H-indol-5-yl)-3-pyridinyl]oxy]-, hydrochloride (1:2), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 959157-95-0 CAPLUS
CN 2H-Indol-2-one, 5-[5-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yloxy]-2-pyridinyl]-1,3-dihydro- (CA INDEX NAME)

Relative stereochemistry.



RN 959157-96-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)-3-pyridinyl]oxy]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 959158-57-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[6-(1H-indol-4-yl)-3-pyridinyl]oxy]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 959158-58-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[6-(1H-indol-4-yl)-3-pyridinyl]oxy]-, (3-endo)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 959158-57-7
CMF C20 H21 N3 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 959394-73-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[6-(1H-indol-5-yl)-3-pyridinyl]oxy]-, hydrochloride (1:2), (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 959394-74-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)-3-pyridinyl]oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



IT 959157-93-8P 959158-13-5P 959394-79-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of fused bicycloheterocycle substituted azabicyclic alkane derivs. useful in treatment and prevention of diseases)

RN 959157-93-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[6-(1H-indol-5-yl)-3-pyridinyl]oxy]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 959158-13-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-chloro-3-pyridinyl)oxy]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 959394-79-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-chloro-3-pyridinyl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.


R
NH
S
O
N
Cl

L4 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:935076 CAPLUS
DOCUMENT NUMBER: 147:300991
TITLE: Preparation of novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
INVENTOR(S): Peters, Dan; Redrobe, John Paul; Nielsen, Elsebet Oestergaard
PATENT ASSIGNEE(S): Neurosearch A/S, Den.
SOURCE: PCT Int. Appl., 27pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007093604	A1	20070823	WO 2007-EP51401	20070213

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: DK 2006-233 A 20060217
US 2006-774669P P 20060221
OTHER SOURCE(S): MARPAT 147:300991
GI



I

AB The title compds. I [Q = chromen-2-one group which is optionally substituted with one or more substituents independently selected from the group consisting of: halo, CF3, OCF3, CN, OH, NH2, NO2, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl; R1 = H or (un)substituted alkyl; R2 and R3 together form CH2CH2 or CH:CH], useful as monoamine neurotransmitter re-uptake inhibitors, were prepared For example, treating exo-7-[(8-tert-butoxycarbonyl-8-aza-bicyclo[3.2.1]oct-3-yl)oxy]-3-bromochromen-2-one with hydrogen chloride in acetic acid at r.t. for 3 h afforded 99% exo-3-bromo-7-[(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)oxy]-3-bromochromo-2-one hydrochloride. A number of compds. I were tested for their ability to inhibit the reuptake of the monoamine neurotransmitters dopamine, noradrenaline and serotonin (data given for representative compds. I). In other aspects the invention relates to the use of the compds. I in a method for therapy and to pharmaceutical compns. comprising the compds. I.
IT 881387-66-2P 947185-43-5P 947185-44-6P

947185-45-7P 947185-46-8P 947185-61-7P
947185-62-8P 947185-63-9P 947185-64-0P
947185-65-1P 947185-83-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel chromenone derivs. as monoamine neurotransmitter reuptake inhibitors useful in treatment and prevention of diseases)

RN 881387-66-2 CAPLUS
CN 2H-1-Benzopyran-2-one, 7-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 947185-43-5 CAPLUS
CN 2H-1-Benzopyran-3-carbonitrile, 7-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-2-oxo-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 947185-44-6 CAPLUS
CN 2H-1-Benzopyran-2-one, 6-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-3-bromo-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 947185-45-7 CAPLUS
CN 2H-1-Benzopyran-2-one, 7-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-3-chloro-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 947185-46-8 CAPLUS
CN 2H-1-Benzopyran-3-carbonitrile, 7-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-4-methyl-2-oxo-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 947185-61-7 CAPLUS
CN 2H-1-Benzopyran-2-one, 7-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-3-bromo- (CA INDEX NAME)

Relative stereochemistry.



RN 947185-62-8 CAPLUS
CN 2H-1-Benzopyran-3-carbonitrile, 7-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-2-oxo- (CA INDEX NAME)

Relative stereochemistry.



RN 947185-63-9 CAPLUS
CN 2H-1-Benzopyran-2-one, 6-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-3-bromo- (CA INDEX NAME)

Relative stereochemistry.



RN 947185-64-0 CAPLUS
CN 2H-1-Benzopyran-2-one, 7-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-3-chloro- (CA INDEX NAME)

Relative stereochemistry.



RN 947185-65-1 CAPLUS
CN 2H-1-Benzopyran-3-carbonitrile, 7-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-4-methyl-2-oxo- (CA INDEX NAME)

Relative stereochemistry.



RN 947185-83-3 CAPLUS
CN 2H-1-Benzopyran-2-one, 7-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-3-bromo-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

IT 881387-68-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of novel chromenone derivs. as monoamine neurotransmitter reuptake inhibitors useful in treatment and prevention of diseases)
RN 881387-68-4 CAPLUS
CN 2H-1-Benzopyran-2-one, 7-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:933108 CAPLUS
DOCUMENT NUMBER: 147:301188
TITLE: Preparation of novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
INVENTOR(S): Schwink, Lothar; Stengelin, Siegfried; Gossel, Matthias; Hessler, Gerhard; Haack, Torsten; Lennig, Petra
PATENT ASSIGNEE(S): Sanofi-Aventis, Fr.
SOURCE: PCT Int. Appl., 166pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007093365	A2	20070823	WO 2007-EP1213	20070213
WO 2007093365	A3	20071004		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: DE 2006-102006007049A 20060215
OTHER SOURCE(S): MARPAT 147:301188
GI



I



I

AB Title compds. I [R1-3 and R6 independently = H, halo, CF3, NO2, etc.; R4 =

H or alkyl; R5 = H, halo, OH , CN, (un)substituted alkoxy, etc.; D = N or CR6; A = bond or 1-8 membered linker; B = H, alkyl, hydroxyalkyl; L = bond or alkylene; Q = (un)saturated bicyclic, tricyclic, spirocyclic ring with 0-3 heteroatoms, or NR7R8 where R7 and R8 independently = H, (un)substituted alkyl, alkoxyalkyl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as MCH antagonists. Thus, e.g., II was prepared by hydrogenation of 6-((Z)-2-ethoxyvinyl)-3-[3-fluoro-4-(2-pyrrolidin-1-ylethoxy)phenyl]-3H-thieno[3,2-d]pyrimidin-4-one (preparation given). In calcium immobilization assays, selected I demonstrated IC50 values ranging from 0.10 - 13.04 μM.

IT 947176-17-2P 947176-33-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel amino alc.-substituted arylthienopyrimidinones as MCH antagonists)

RN 947176-17-2 CAPLUS
CN Thieno[3,2-d]pyrimidin-4(3H)-one, 3-[4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yloxy]phenyl]-6-(4-chlorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 947176-33-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-nitrophenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:932835 CAPLUS
DOCUMENT NUMBER: 147:301001
TITLE: Preparation of aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
INVENTOR(S): Schwink, Lothar; Stengelin, Siegfried; Gossel, Matthias; Hessler, Gerhard; Haack, Torsten; Lennig, Petra
PATENT ASSIGNEE(S): Sanofi-Aventis, Fr.
SOURCE: PCT Int. Appl., 140pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007093366	A1	20070823	WO 2007-EP1214	20070213

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: DE 2006-102006007048A 20060215
OTHER SOURCE(S): MARPAT 147:301001
GI



I



II

AB Title compds. I [D = N, CR5; R1, R2, R3, and R5 independently = H, halo, OH, CF3, alkoxy, etc.; R4 = H, halo, CF3O, alkyl, alkenyl, etc.; A = bond or 1-8 membered linker; B = H, hydroxyalkyl, alkoxyalkyl, etc.; X = S, O,

C(R6)=C(R7); R6 and R7 independently = H, halo, NO2, CN, CO2H, etc.; Y = C(R8)(R9)C(R10)(R11) or C(R12)=C(R13); R8-13 independently = H or alkyl; L = bond or alkylene; Q = NH2, NH-alkyl, (un)saturated (un)substituted bicyclic, tricyclic, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as MCH antagonists. Thus, e.g., II was prepared by alkylation of 2-[3-chloro-4-((1R,3R,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yloxy)phenyl]-6-hydroxy-3,4-dihydro-2H-isoquinolin-1-one (preparation given) with 1-iodopropane. In calcium immobilization assays, selected I demonstrated IC50 values ranging from 0.13 - 14.84 μM.

IT 947234-34-6P 947234-59-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoalc.-substituted aryldihydroisoquinolinones as MCH antagonists)

RN 947234-34-6 CAPLUS
CN 1(2H)-Isoquinolinone, 2-[4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yloxy]-3-chlorophenyl]-6-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 947234-59-5 CAPLUS
CN 1(2H)-Isoquinolinone, 2-[4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yloxy]phenyl]-3,4-dihydro-6-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



IT 947234-80-2 947234-81-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aminoalc.-substituted aryldihydroisoquinolinones as MCH antagonists)

RN 947234-80-2 CAPLUS
CN 1(2H)-Isoquinolinone, 2-[4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yloxy]-3-fluorophenyl]-3,4-dihydro-6-[[(2R)-tetrahydro-2-furanyl]methoxy]- (CA

INDEX NAME)

Absolute stereochemistry.



RN 947234-81-3 CAPLUS
CN 1(2H)-Isoquinolinone, 2-[4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yloxy]phenyl]-6-[[(2S)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



IT 947234-69-7P 947234-74-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminoalc.-substituted aryldihydroisoquinolinones as MCH antagonists)
RN 947234-69-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(2-fluoro-4-nitrophenoxy)-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 947234-74-4 CAPLUS
CN 1(2H)-Isoquinolinone, 2-[4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yloxy]-3-fluorophenyl]-6-[[(2R)-tetrahydro-2-furanyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:873791 CAPLUS
DOCUMENT NUMBER: 147:235029
TITLE: Preparation of 8-azabicyclo[3.2.1]octane derivatives as monoamine neurotransmitter reuptake inhibitors
INVENTOR(S): Napier, Susan Elizabeth; Bingham, Matilda Jane; Dunbar, Neil Andrew
PATENT ASSIGNEE(S): N.V. Organon, Neth.
SOURCE: U.S. Pat. Appl. Publ., 35pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2007185156	A1	20070809	US 2006-607574		20061201
PRIORITY APPLN. INFO.:			US 2005-741320P	P	20051201

OTHER SOURCE(S): MARPAT 147:235029
GI



I

AB The title 8-azabicyclo[3.2.1]octane derivs. [I; wherein R1 = H or C1-5 alkyl; Y = O, S or O(CH2)m; m = 1, 2; n = 0,1; Ar1 = each (un)substituted phenylene or pyridylene, said phenylene and pyridylene being 1,3-linked with respect to O and when n is 1 with Y and when n is 0 with Ar2; Ar2 = each (un)substituted Ph or 5-6 membered heteroaryl] or pharmaceutically acceptable salts or solvates thereof are prepared These compds. are monoamine neurotransmitter reuptake inhibitors which in vitro inhibit the reuptake of one or more of serotonin, noradrenaline and dopamine in cells stably transfected with the human serotonin, noradrenaline, and dopamine transporters. They are useful for the treatment or prevention of diseases for which the reuptake inhibition of one or more monoamines contributes to the therapeutic effect, e.g. a disease or disorder of the nervous system, both centrally and peripherally which is responsive to monoamine neurotransmission reuptake, more specifically depression, anxiety, pain, panic disorders, attention deficit hyperactivity disorder (ADHD), or obsessive compulsive disorder. Thus, di-Et azodicarboxylate (1.89 mL) was added dropwise to a solution of endo-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-Bu ester (2.27 g), Ph3P (3.15 g) and 3-phenoxyphenol (1.93 mL) in 60 mL THF. The reaction mixture was stirred under a nitrogen atmospheric for 72 h at ambient temperature to give, after workup, silica gel chromatog., and treatment with HCl in methanol, 3-exo-(3-phenoxyphenoxy)-8-azabicyclo[3.2.1]octane hydrochloride. In vitro test for the inhibition of dopamine and serotonin uptake was performed in Chinese hamster ovary cells expressing the human dopamine transporter (hDAT) or the human serotonin transporter (hSERT) and in vitro test for the inhibition of noradrenaline uptake was performed in Madin Darby canine kidney cells (MDCK) expressing the human noradrenaline transporter (hNET). 3-Exo-(3-chloro-5-phenoxyphenoxy)-8-azabicyclo[3.2.1]octane showed pEC50 of >7, 6-7, and <6 for hDAT, hNET, and hSERT, resp.
IT 939788-79-1P, exo-3'-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]biphenyl-4-

carbonitrile
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 8-azabicyclo[3.2.1]octane derivs. as monoamine neurotransmitter reuptake inhibitors)
RN 939788-79-1 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 3'-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]- (CA INDEX NAME)

Relative stereochemistry.



IT 817195-02-1P, 3-exo-[(Dibenzofuran-2-yl)oxy]-8-azabicyclo[3.2.1]octane 939788-34-8P, 3-exo-(3-Phenoxyphenoxy)-8-azabicyclo[3.2.1]octane 939788-35-9P, 3-exo-[4-Chloro-3-(4-fluorophenoxy)phenoxy]-8-azabicyclo[3.2.1]octane 939788-36-0P, 3-exo-[(5-Chlorobiphenyl-3-yl)oxy]-8-azabicyclo[3.2.1]octane 939788-37-1P, 3-exo-[(5-Bromobiphenyl-3-yl)oxy]-8-azabicyclo[3.2.1]octane 939788-38-2P, exo-5-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]biphenyl-3-carbonitrile 939788-39-3P, 3-exo-([1,1';3',1'']Terphenyl-5'-yloxy)-8-azabicyclo[3.2.1]octane 939788-40-6P, 3-exo-[(5-Fluorobiphenyl-3-yl)oxy]-8-azabicyclo[3.2.1]octane 939788-41-7P, 3-exo-[(6-Fluorobiphenyl-3-yl)oxy]-8-azabicyclo[3.2.1]octane 939788-42-8P, 3-exo-[(Biphenyl-3-yl)oxy]-8-azabicyclo[3.2.1]octane 939788-43-9P, 3-exo-[(6-Chlorobiphenyl-3-yl)oxy]-8-azabicyclo[3.2.1]octane 939788-44-0P, 3-exo-(4-Chloro-3-phenoxyphenoxy)-8-azabicyclo[3.2.1]octane 939788-45-1P, 3-exo-(2-Chloro-5-phenoxyphenoxy)-8-azabicyclo[3.2.1]octane 939788-46-2P, 3-exo-[(4-Bromobiphenyl-3-yl)oxy]-8-azabicyclo[3.2.1]octane 939788-47-3P, 3-exo-[(6-Bromobiphenyl-3-yl)oxy]-8-azabicyclo[3.2.1]octane 939788-48-4P, 3-exo-(4-Bromo-3-phenoxyphenoxy)-8-azabicyclo[3.2.1]octane 939788-49-5P, exo-5-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]biphenyl-2-carbonitrile 939788-50-8P, 3-exo-(3-Phenethyloxyphenoxy)-8-azabicyclo[3.2.1]octane 939788-51-9P, 3-exo-[[3-(Thiophen-2-yl)phenyl]oxy]-8-azabicyclo[3.2.1]octane 939788-53-1P, 3-exo-[3-(3-Chlorophenoxy)-4-fluorophenoxy]-8-azabicyclo[3.2.1]octane 939788-54-2P, 3-exo-[3-(3,4-Dichlorophenoxy)-4-fluorophenoxy]-8-azabicyclo[3.2.1]octane 939788-55-3P, 3-exo-[3-(4-Chlorophenoxy)-4-fluorophenoxy]-8-azabicyclo[3.2.1]octane 939788-56-4P, 3-exo-[4-Fluoro-3-(3-methoxyphenoxy)phenoxy]-8-azabicyclo[3.2.1]octane 939788-57-5P, exo-3-[5-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-2-fluorophenoxy]benzonitrile 939788-58-6P, exo-3-[3-[(Pyridin-3-yl)oxy]phenoxy]-8-azabicyclo[3.2.1]octane 939788-59-7P, 3-exo-[(6-Phenylpyridin-2-yl)oxy]-8-azabicyclo[3.2.1]octane 939788-60-0P, 3-exo-[(2-Phenylpyridin-4-yl)oxy]-8-azabicyclo[3.2.1]octane 939788-61-1P, 3-exo-[(4-Phenylpyridin-2-yl)oxy]-8-azabicyclo[3.2.1]octane 939788-62-2P, 3-exo-[[3-(Pyridin-3-yl)phenyl]oxy]-8-azabicyclo[3.2.1]octane 939788-63-3P, exo-1-[3'-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]biphenyl-4-yl]ethanone 939788-64-4P, 3-exo-[(4'-Trifluoromethylbiphenyl-3-

yl)oxy]-8-azabicyclo[3.2.1]octane 939788-65-5P,
3-exo-[(4-Chlorobiphenyl-3-yl)oxy]-8-azabicyclo[3.2.1]octane
939788-66-6P, 3-exo-[(2'-Chlorobiphenyl-3-yl)oxy]-8-
azabicyclo[3.2.1]octane 939788-67-7P, 3-exo-[(3'-Chlorobiphenyl-
3-yl)oxy]-8-azabicyclo[3.2.1]octane 939788-68-8P,
3-exo-[(4'-Chlorobiphenyl-3-yl)oxy]-8-azabicyclo[3.2.1]octane
939788-69-9P, 3-exo-[(2'-Fluorobiphenyl-3-yl)oxy]-8-
azabicyclo[3.2.1]octane 939788-70-2P, 3-exo-[(4'-Fluorobiphenyl-
3-yl)oxy]-8-azabicyclo[3.2.1]octane 939788-71-3P,
3-exo-[(2'-Trifluoromethylbiphenyl-3-yl)oxy]-8-azabicyclo[3.2.1]octane
939788-72-4P, 3-exo-(2-Fluoro-3-methoxy-5-phenoxyphenoxy)-8-
azabicyclo[3.2.1]octane 939788-73-5P, 3-exo-[[3'-
(Trifluoromethoxy)biphenyl-3-yl]oxy]-8-azabicyclo[3.2.1]octane
939788-74-6P, 3-exo-[(2'-Methylbiphenyl-3-yl)oxy]-8-
azabicyclo[3.2.1]octane 939788-75-7P, 3-exo-[(3'-Methylbiphenyl-
3-yl)oxy]-8-azabicyclo[3.2.1]octane 939788-76-8P,
3-exo-(3-Phenoxy-4-trifluoromethylphenoxy)-8-azabicyclo[3.2.1]octane
939788-77-9P, exo-3'-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]biphenyl-2-
carbonitrile 939788-78-0P, exo-3'-[(8-Azabicyclo[3.2.1]oct-3-
yl)oxy]biphenyl-3-carbonitrile 939788-80-4P,
3-exo-(3-Phenoxy-5-trifluoromethylphenoxy)-8-azabicyclo[3.2.1]octane
939788-81-5P, 3-exo-(4-Methyl-3-phenoxyphenoxy)-8-
azabicyclo[3.2.1]octane 939788-82-6P, 3-exo-(3-Chloro-5-
phenoxyphenoxy)-8-azabicyclo[3.2.1]octane 939788-83-7P,
exo-3-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-5-phenoxybenzonitrile
939788-84-8P, 3-exo-[(3'-Fluorobiphenyl-3-yl)oxy]-8-
azabicyclo[3.2.1]octane 939788-85-9P, 3-exo-[(3'-
Trifluoromethylbiphenyl-3-yl)oxy]-8-azabicyclo[3.2.1]octane
939788-86-0P, 3-exo-[[4'-(Trifluoromethoxy)biphenyl-3-yl]oxy]-8-
azabicyclo[3.2.1]octane 939788-87-1P, 3-exo-[(2'-Methoxybiphenyl-
3-yl)oxy]-8-azabicyclo[3.2.1]octane 939788-88-2P,
3-exo-[(3'-Methoxybiphenyl-3-yl)oxy]-8-azabicyclo[3.2.1]octane
939788-90-6P, 3-exo-[(4'-Methoxybiphenyl-3-yl)oxy]-8-
azabicyclo[3.2.1]octane 939788-93-9P, 3-exo-[(4-Methylbiphenyl-3-
yl)oxy]-8-azabicyclo[3.2.1]octane 939788-94-0P,
exo-3'-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-2'-fluorobiphenyl-4-carbonitrile
939788-95-1P, exo-3-[[2'-(Trifluoromethoxy)biphenyl-3-yl]oxy]-8-
azabicyclo[3.2.1]octane 939788-98-4P, 3-exo-[(6-Methylbiphenyl-3-
yl)oxy]-8-azabicyclo[3.2.1]octane 939788-99-5P,
3-exo-[(6-Trifluoromethylbiphenyl-3-yl)oxy]-8-azabicyclo[3.2.1]octane
939789-00-1P, exo-3-[3-Fluoro-5-(pyridin-4-yl)phenoxy]-8-
azabicyclo[3.2.1]octane 939789-01-2P, exo-3-[3-Chloro-5-(pyridin-
4-yl)phenoxy]-8-azabicyclo[3.2.1]octane 939789-02-3P,
exo-3-[4-Chloro-3-[(pyridin-3-yl)oxy]phenoxy]-8-azabicyclo[3.2.1]octane
939789-03-4P, exo-3-[4-Methyl-3-(pyridin-4-yl)phenoxy]-8-
azabicyclo[3.2.1]octane 939789-04-5P, exo-5-[(8-
Azabicyclo[3.2.1]oct-3-yl)oxy]biphenyl-3,4'-dicarbonitrile
939789-05-6P, exo-3'-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-5'-
chlorobiphenyl-4-carbonitrile 939789-07-8P, 3-exo-[(4,6-
Diphenylpyridin-2-yl)oxy]-8-azabicyclo[3.2.1]octane 939789-08-9P
, exo-4-[6-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-4-chloropyridin-2-
yl]benzonitrile 939789-09-0P, exo-4-[2-[(8-Azabicyclo[3.2.1]oct-
3-yl)oxy]-6-chloropyridin-4-yl]benzonitrile 939789-10-3P,
3-exo-[[3-(Pyridin-4-yl)phenyl]oxy]-8-azabicyclo[3.2.1]octane
939789-11-4P, exo-4-[6-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]pyridin-2-
yl]benzonitrile 939789-12-5P, exo-2-[4-[(8-Azabicyclo[3.2.1]oct-
3-yl)oxy]-6-chloropyridin-2-yl]benzonitrile 939789-13-6P,
exo-2-[6-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-4-chloropyridin-2-
yl]benzonitrile 939789-14-7P, exo-2-[6-[(8-Azabicyclo[3.2.1]oct-
3-yl)oxy]-4-chloropyridin-2-yl]benzamide 939789-15-8P,
exo-2-[2-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-6-chloropyridin-4-
yl]benzonitrile 939789-16-9P, exo-2-[6-[(8-Azabicyclo[3.2.1]oct-

3-yl)oxy]pyridin-2-yl]benzonitrile 939789-17-0P,
exo-4-[2-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]pyridin-4-yl]benzonitrile
939789-18-1P, exo-4-[4-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]pyridin-2-
yl]benzonitrile 939789-19-2P, exo-3-[(4,5-Difluorobiphenyl-3-
yl)oxy]-8-azabicyclo[3.2.1]octane 939789-20-5P,
exo-3-[(5-Trifluoromethylbiphenyl-3-yl)oxy]-8-azabicyclo[3.2.1]octane
939789-21-6P, exo-2-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-6-
phenylisonicotinonitrile 939789-22-7P, exo-2-[(8-
Azabicyclo[3.2.1]oct-3-yl)oxy]-6-(4-cyanophenyl)isonicotinonitrile
939789-23-8P, exo-2-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-6-(2-
cyanophenyl)isonicotinonitrile 939789-24-9P,
exo-2-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-6-(2-
trifluoromethylphenyl)isonicotinonitrile 939789-25-0P,
exo-2-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-6-(2-
methoxyphenyl)isonicotinonitrile 939789-26-1P,
exo-2-[6-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-4-chloropyridin-2-yl]benzoic
acid 939789-27-2P, exo-2-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-6-(3-
fluorophenyl)isonicotinonitrile 939789-28-3P,
exo-3-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-5-(3-fluoropyridin-2-
yl)benzonitrile 939789-29-4P, exo-3-[(8-Azabicyclo[3.2.1]oct-3-
yl)oxy]-5-(3-chloropyridin-2-yl)benzonitrile 939789-30-7P,
exo-6-[3-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-5-cyanophenyl]nicotinonitrile
939789-31-8P, exo-3-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-5-[3-
(trifluoromethyl)pyridin-2-yl]benzonitrile 939789-32-9P,
exo-3-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-5-(pyridin-2-yl)benzonitrile
939789-33-0P, exo-3-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-5-(3,5-
dichloropyridin-2-yl)benzonitrile 939789-34-1P,
exo-3-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-5-(3-methoxypyridin-2-
yl)benzonitrile 939789-35-2P, exo-N-[2-[3-[(8-
Azabicyclo[3.2.1]oct-3-yl)oxy]-5-cyanophenyl]pyridin-3-yl]acetamide
939789-36-3P, exo-2-[3-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-5-
cyanophenyl]nicotinonitrile 939789-37-4P, exo-3-[(8-
Azabicyclo[3.2.1]oct-3-yl)oxy]-5-(pyrimidin-2-yl)benzonitrile
939789-38-5P, exo-3-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-5-
(Pyrimidin-5-yl)benzonitrile 939789-39-6P, exo-3-[(8-
Azabicyclo[3.2.1]oct-3-yl)oxy]-5-(isoquinolin-1-yl)benzonitrile
939789-40-9P, 3-exo-[(5-Chloro-6-phenoxypyridin-2-yl)oxy]-8-
azabicyclo[3.2.1]octane 939789-41-0P, 3-exo-[(6-Phenoxypyridin-2-
yl)oxy]-8-azabicyclo[3.2.1]octane 939960-38-0P,
3-endo-(3-Phenoxyphenoxy)-8-azabicyclo[3.2.1]octane 945565-28-6P
, 3-exo-(3-Phenoxyphenoxy)-8-azabicyclo[3.2.1]octane hydrochloride
945565-29-7P, 3-exo-(4-Fluoro-3-phenoxyphenoxy)-8-
azabicyclo[3.2.1]octane trifluoroacetate 945565-30-0P,
3-exo-[(4'-Trifluoromethylbiphenyl-3-yl)oxy]-8-azabicyclo[3.2.1]octane
trifluoroacetate 945565-31-1P, 3-exo-[(5-Phenylpyridin-3-yl)oxy]-
8-azabicyclo[3.2.1]octane 945565-32-2P, 3-exo-[(6-Methylbiphenyl-
3-yl)oxy]-8-azabicyclo[3.2.1]octane trifluoroacetate 945565-33-3P***,
3-exo-[(4-Chloro-6-Phenylpyridin-2-yl)oxy]-8-azabicyclo[3.2.1]octane
trifluoroacetate ***945565-35-5P, exo-2-[(8-Azabicyclo[3.2.1]oct-3-
yl)oxy]-6-phenylisonicotinonitrile trifluoroacetate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of 8-azabicyclo[3.2.1]octane derivs. as monoamine
neurotransmitter reuptake inhibitors)

RN 817195-02-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-(2-dibenzofuranyloxy)-, (3-exo)- (CA INDEX
NAME)

Relative stereochemistry.



RN 939788-34-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(3-phenoxyphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-35-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-chloro-3-(4-fluorophenoxy)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-36-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(5-chloro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-37-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(5-bromo[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-38-2 CAPLUS
CN [1,1'-Biphenyl]-3-carbonitrile, 5-(8-azabicyclo[3.2.1]oct-3-yloxy)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-39-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-([1,1':3',1''-terphenyl]-5'-yloxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-40-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(5-fluoro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-41-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-fluoro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-42-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-([1,1'-biphenyl]-3-yloxy)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-43-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-chloro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-44-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-chloro-3-phenoxyphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-45-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(2-chloro-5-phenoxyphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-46-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-bromo[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-47-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-bromo[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-48-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-bromo-3-phenoxyphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-49-5 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5-(8-azabicyclo[3.2.1]oct-3-yloxy)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-50-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(2-phenylethoxy)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-51-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(2-thienyl)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-53-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(3-chlorophenoxy)-4-fluorophenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-54-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(3,4-dichlorophenoxy)-4-fluorophenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-55-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(4-chlorophenoxy)-4-fluorophenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-56-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-fluoro-3-(3-methoxyphenoxy)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-57-5 CAPLUS
CN Benzonitrile, 3-[5-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-2-fluorophenoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-58-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(3-pyridinyloxy)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-59-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-phenyl-2-pyridinyl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-60-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(2-phenyl-4-pyridinyl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-61-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-phenyl-2-pyridinyl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-62-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(3-pyridinyl)phenoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-63-3 CAPLUS
CN Ethanone, 1-[3'-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-64-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-65-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-chloro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-66-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(2'-chloro[1,1'-biphenyl]-3-yl)oxy]- (CA

INDEX NAME)

Relative stereochemistry.



RN 939788-67-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(3'-chloro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-68-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4'-chloro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-69-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(2'-fluoro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-70-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4'-fluoro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-71-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-72-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(2-fluoro-3-methoxy-5-phenoxyphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-73-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[3'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-74-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(2'-methyl[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-75-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(3'-methyl[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-76-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-phenoxy-4-(trifluoromethyl)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-77-9 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 3'-(8-azabicyclo[3.2.1]oct-3-yloxy)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-78-0 CAPLUS
CN [1,1'-Biphenyl]-3-carbonitrile, 3'-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-80-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-phenoxy-5-(trifluoromethyl)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-81-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-methyl-3-phenoxyphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-82-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-(3-chloro-5-phenoxyphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-83-7 CAPLUS
CN Benzonitrile, 3-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-5-phenoxy- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-84-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(3'-fluoro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-85-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-86-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[4'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-87-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(2'-methoxy[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-88-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(3'-methoxy[1,1'-biphenyl]-3-yl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-90-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4'-methoxy[1,1'-biphenyl]-3-yl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-93-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-methyl[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-94-0 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 3'-(8-azabicyclo[3.2.1]oct-3-yloxy)-2'-fluoro- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-95-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-98-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-methyl[1,1'-biphenyl]-3-yl)oxy]- (CA

INDEX NAME)

Relative stereochemistry.



RN 939788-99-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[6-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-00-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-fluoro-5-(4-pyridinyl)phenoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-01-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-chloro-5-(4-pyridinyl)phenoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-02-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-chloro-3-(3-pyridinyloxy)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-03-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-methyl-3-(4-pyridinyl)phenoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-04-5 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarbonitrile, 5-(8-azabicyclo[3.2.1]oct-3-yloxy)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-05-6 CAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 3'-(8-azabicyclo[3.2.1]oct-3-yloxy)-5'-chloro- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-07-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4,6-diphenyl-2-pyridinyl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-08-9 CAPLUS
CN Benzonitrile, 4-[6-(8-azabicyclo[3.2.1]oct-3-yloxy)-4-chloro-2-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-09-0 CAPLUS
CN Benzonitrile, 4-[2-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-chloro-4-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-10-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(4-pyridinyl)phenoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-11-4 CAPLUS
CN Benzonitrile, 4-[6-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-2-pyridinyl]-
(CA INDEX NAME)

Relative stereochemistry.



RN 939789-12-5 CAPLUS
CN Benzonitrile, 2-[4-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-chloro-2-pyridinyl]-
(CA INDEX NAME)

Relative stereochemistry.



RN 939789-13-6 CAPLUS
CN Benzonitrile, 2-[6-(8-azabicyclo[3.2.1]oct-3-yloxy)-4-chloro-2-pyridinyl]-
(CA INDEX NAME)

Relative stereochemistry.



RN 939789-14-7 CAPLUS
CN Benzamide, 2-[6-(8-azabicyclo[3.2.1]oct-3-yloxy)-4-chloro-2-pyridinyl]-
(CA INDEX NAME)

Relative stereochemistry.



RN 939789-15-8 CAPLUS
CN Benzonitrile, 2-[2-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-chloro-4-pyridinyl]-
(CA INDEX NAME)

Relative stereochemistry.



RN 939789-16-9 CAPLUS
CN Benzonitrile, 2-[6-(8-azabicyclo[3.2.1]oct-3-yloxy)-2-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-17-0 CAPLUS
CN Benzonitrile, 4-[2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-4-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-18-1 CAPLUS
CN Benzonitrile, 4-[4-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-2-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-19-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4,5-difluoro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-20-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[5-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-21-6 CAPLUS
CN 4-Pyridinecarbonitrile, 2-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-phenyl- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-22-7 CAPLUS
CN 4-Pyridinecarbonitrile, 2-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-(4-cyanophenyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-23-8 CAPLUS
CN 4-Pyridinecarbonitrile, 2-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-(2-cyanophenyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-24-9 CAPLUS
CN 4-Pyridinecarbonitrile, 2-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-25-0 CAPLUS
CN 4-Pyridinecarbonitrile, 2-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-(2-methoxyphenyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-26-1 CAPLUS
CN Benzoic acid, 2-[6-(8-azabicyclo[3.2.1]oct-3-yloxy)-4-chloro-2-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-27-2 CAPLUS
CN 4-Pyridinecarbonitrile, 2-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-(3-fluorophenyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-28-3 CAPLUS
CN Benzonitrile, 3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-(3-fluoro-2-pyridinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-29-4 CAPLUS
CN Benzonitrile, 3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-(3-chloro-2-pyridinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-30-7 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-cyanophenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-31-8 CAPLUS
CN Benzonitrile, 3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-[3-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-32-9 CAPLUS
CN Benzonitrile, 3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-(2-pyridinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-33-0 CAPLUS
CN Benzonitrile, 3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-(3,5-dichloro-2-pyridinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-34-1 CAPLUS
CN Benzonitrile, 3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-(3-methoxy-2-pyridinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-35-2 CAPLUS
CN Acetamide, N-[2-[3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-cyanophenyl]-3-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-36-3 CAPLUS
CN 3-Pyridinecarbonitrile, 2-[3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-cyanophenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-37-4 CAPLUS
CN Benzonitrile, 3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-(2-pyrimidinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-38-5 CAPLUS
CN Benzonitrile, 3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-(5-pyrimidinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-39-6 CAPLUS
CN Benzonitrile, 3-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-5-(1-isoquinolinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-40-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(5-chloro-6-phenoxy-2-pyridinyl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-41-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-phenoxy-2-pyridinyl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939960-38-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(3-phenoxyphenoxy)-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 945565-28-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-(3-phenoxyphenoxy)-, hydrochloride (1:1), (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 945565-29-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-fluoro-3-phenoxyphenoxy)-, (3-exo)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 939788-52-0
CMF C19 H20 F N O2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 945565-30-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 939788-64-4
CMF C20 H20 F3 N O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 945565-31-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(5-phenyl-3-pyridinyl)oxy]- (CA INDEX NAME)



RN 945565-32-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-methyl[1,1'-biphenyl]-3-yl)oxy]-,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 939788-98-4
CMF C20 H23 N O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 945565-33-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-chloro-6-phenyl-2-pyridinyl)oxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 939789-06-7
CMF C18 H19 Cl N2 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 945565-35-5 CAPLUS
CN 4-Pyridinecarbonitrile, 2-[2-(8-azabicyclo[3.2.1]oct-3-yloxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 945565-34-4
CMF C19 H19 N3 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L4 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:761334 CAPLUS
DOCUMENT NUMBER: 147:166196
TITLE: Bicyclic nitrogen compounds as modulators of ghrelin receptor and their preparation, pharmaceutical compositions and use in the treatment of diseases
INVENTOR(S): Burstein, Ethan; Eeg Knapp, Anne; Olsson, Roger; Eskildsen, Jorgen; Ek, Fredrik
PATENT ASSIGNEE(S): Acadia Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 481pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007079239	A2	20070712	WO 2006-US49609	20061229
WO 2007079239	A3	20071101		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 2007213359	A1	20070913	US 2006-618724	20061229
PRIORITY APPLN. INFO.:			US 2005-755714P P	20051230
			US 2006-835241P P	20060802

OTHER SOURCE(S): MARPAT 147:166196
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed herein are compds. of formula I as defined herein, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, that modulates the activity of a ghrelin receptor. Disclosed herein are also methods of treating diseases or conditions that comprise administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. Compds. of formula I wherein A is H, halo, CN, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted (hetero)aryl, etc.; B is H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted (hetero)aryl, etc.; Y is CR3 and N R2 and R2a are independently H, CN, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted (hetero)aryl, etc; R3, R3a, R3b, and R3c are independently H, halo, CN, NO2, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted (hetero)aryl, etc.; L is (un)substituted alkylene; L can be taken together with R3 to form a cycloalkyl, cycloalkenyl, cycloalkynyl and heteroalicyclyl; and their solvates, polymorphs, metabolites, pharmaceutically acceptable salts and prodrugs thereof, are claimed. Example compound II was prepared by amination of 1-[1-(3-chlorophenoxy)-7-methoxy-1H-indol-3-yl]ethanone with

4-(4-fluorophenoxy)piperidine hydrochloride; the resulting compound II was added oxalic acid to give the corresponding salt. All the invention compds. were evaluated for their ghrelin receptor modulatory activity (some data given).

IT 652148-02-2P 845291-48-7P 944086-54-8P
RL: CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of bicyclic nitrogen compds. as modulators of ghrelin receptors for treating various diseases)

RN 652148-02-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-fluorophenoxy)-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 845291-48-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-chlorophenoxy)-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 944086-54-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(2-chlorophenoxy)-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



IT 944086-73-1
RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)
(starting material; preparation of bicyclic nitrogen compds. as modulators of ghrelin receptors for treating various diseases)

RN 944086-73-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-chlorophenoxy)- (CA INDEX NAME)


Cl
NH
O

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:619810 CAPLUS
DOCUMENT NUMBER: 147:53047
TITLE: Preparation of 8-azabicyclo[3.2.1]octane derivatives useful as mono-amine reuptake inhibitors
INVENTOR(S): Napier, Susan Elizabeth; Bingham, Matilda Jane; Dunbar, Neil Andrew
PATENT ASSIGNEE(S): N.V. Organon, Neth.
SOURCE: PCT Int. Appl., 68pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007063071	A1	20070607	WO 2006-EP69047	20061129

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2005-111578 A 20051201
OTHER SOURCE(S): MARPAT 147:53047
GI



I

AB The present invention relates to a 8-azabicyclo[3.2.1]octane derivs. I, wherein R1 is H or C1-5-alkyl; Y is O, S, O(CH2)m; m is 1 or 2; n is 0 or 1; Ar1 is phenylene or pyridylene, said phenylene and pyridylene being 1,3-linked with respect to O and when n is 1 with Y and when n is 0 with Ar2, said phenylene or pyridylene being optionally substituted with one or two substituents independently selected from halogen, C1-5-alkyl, C1-5-alkoxy, C3-6-cycloalkyl, C2-5-alkenyl, C2-5-alkynyl, Ph, CN and hydroxy, wherein said C1-5-alkyl and C1-5-alkoxy are optionally substituted with one to three halogens and wherein the oxygen of said hydroxy is optionally bonded to Ar2 to form a 5-membered ring; Ar2 is Ph or a 5-6 membered heteroaryl, said Ph or 5-6 membered heteroaryl being optionally substituted with one to three substituents independently selected from halogen, C1-5-alkyl, C1-5-alkoxy, CN, CONR2R3, CO2R4, NHCOR5 and hydroxy, wherein said C1-5-alkyl and C1-5-alkoxy are optionally substituted with one to three halogens and wherein the oxygen of said hydroxy is optionally bonded to Ar1 to form a 5-membered ring; R2-R4 are independently H or C1-5-alkyl and R5 is C1-5-alkyl, or a pharmaceutically acceptable salt or solvate thereof for the treatment or prevention of

depression or pain. The present invention are useful for the manufacture of a medicament for the treatment or prevention of a disease or disorder of the nervous system, both centrally and peripherally which is responsive to monoamine neurotransmission reuptake. Thus, exo-3-(3-chloro-5-phenoxyphenoxy)-8-azabicyclo[3.2.1]octane was prepared and tested in vitro as mono-amine reuptake inhibitors. The in vitro test for the inhibition of dopamine and serotonin uptake was performed in Chinese Hamster Ovary cells expressing the human dopamine transporter (hDAT) or the human serotonin transporter (hSERT). The in vitro test for the inhibition of noradrenaline uptake was performed in Madin Darby Canine Kidney Cells (MDCK) expressing the human noradrenaline transporter (hNET).

IT 817195-02-1P 939788-34-8P 939788-35-9P
939788-36-0P 939788-37-1P 939788-38-2P
939788-39-3P 939788-40-6P 939788-41-7P
939788-42-8P 939788-43-9P 939788-44-0P
939788-45-1P 939788-46-2P 939788-47-3P
939788-48-4P 939788-49-5P 939788-50-8P
939788-51-9P 939788-52-0P 939788-53-1P
939788-54-2P 939788-55-3P 939788-56-4P
939788-57-5P 939788-58-6P 939788-59-7P
939788-60-0P 939788-61-1P 939788-62-2P
939788-63-3P 939788-64-4P 939788-65-5P
939788-66-6P 939788-67-7P 939788-68-8P
939788-69-9P 939788-70-2P 939788-71-3P
939788-72-4P 939788-73-5P 939788-74-6P
939788-75-7P 939788-76-8P 939788-77-9P
939788-78-0P 939788-79-1P 939788-80-4P
939788-81-5P 939788-82-6P 939788-83-7P
939788-84-8P 939788-85-9P 939788-86-0P
939788-87-1P 939788-88-2P 939788-90-6P
939788-91-7P 939788-92-8P 939788-93-9P
939788-94-0P 939788-95-1P 939788-98-4P
939788-99-5P 939789-00-1P 939789-01-2P
939789-02-3P 939789-03-4P 939789-04-5P
939789-05-6P 939789-06-7P 939789-07-8P
939789-08-9P 939789-09-0P 939789-10-3P
939789-11-4P 939789-12-5P 939789-13-6P
939789-14-7P 939789-15-8P 939789-16-9P
939789-17-0P 939789-18-1P 939789-19-2P
939789-20-5P 939789-21-6P 939789-22-7P
939789-23-8P 939789-24-9P 939789-25-0P
939789-26-1P 939789-27-2P 939789-28-3P
939789-29-4P 939789-30-7P 939789-31-8P
939789-32-9P 939789-33-0P 939789-34-1P
939789-35-2P 939789-36-3P 939789-37-4P
939789-38-5P 939789-39-6P 939789-40-9P
939789-41-0P 939960-38-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 8-azabicyclo[3.2.1]octane derivs. useful as mono-amine reuptake inhibitors)

RN 817195-02-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-(2-dibenzofuranyloxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-34-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(3-phenoxyphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-35-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-chloro-3-(4-fluorophenoxy)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-36-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(5-chloro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-37-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(5-bromo[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-38-2 CAPLUS
CN [1,1'-Biphenyl]-3-carbonitrile, 5-(8-azabicyclo[3.2.1]oct-3-yloxy)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-39-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-([1,1':3',1''-terphenyl]-5'-yloxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-40-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(5-fluoro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-41-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-fluoro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-42-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-([1,1'-biphenyl]-3-yloxy)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-43-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-chloro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-44-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-chloro-3-phenoxyphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-45-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(2-chloro-5-phenoxyphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-46-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-bromo[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-47-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-bromo[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-48-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-bromo-3-phenoxyphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-49-5 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 5-(8-azabicyclo[3.2.1]oct-3-yloxy)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-50-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(2-phenylethoxy)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-51-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(2-thienyl)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-52-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-fluoro-3-phenoxyphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-53-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[3-(3-chlorophenoxy)-4-fluorophenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-54-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(3,4-dichlorophenoxy)-4-fluorophenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-55-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(4-chlorophenoxy)-4-fluorophenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-56-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-fluoro-3-(3-methoxyphenoxy)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-57-5 CAPLUS
CN Benzonitrile, 3-[5-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-2-fluorophenoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-58-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(3-pyridinyloxy)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-59-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-phenyl-2-pyridinyl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-60-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(2-phenyl-4-pyridinyl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-61-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-phenyl-2-pyridinyl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-62-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(3-pyridinyl)phenoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-63-3 CAPLUS
CN Ethanone, 1-[3'-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-64-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-65-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-chloro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-66-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(2'-chloro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-67-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(3'-chloro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-68-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4'-chloro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-69-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(2'-fluoro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-70-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4'-fluoro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-71-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-72-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(2-fluoro-3-methoxy-5-phenoxyphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-73-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[3'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-74-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(2'-methyl[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-75-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(3'-methyl[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-76-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-phenoxy-4-(trifluoromethyl)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-77-9 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 3'-(8-azabicyclo[3.2.1]oct-3-yloxy)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-78-0 CAPLUS
CN [1,1'-Biphenyl]-3-carbonitrile, 3'-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-79-1 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 3'-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-80-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-phenoxy-5-(trifluoromethyl)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-81-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-methyl-3-phenoxyphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-82-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(3-chloro-5-phenoxyphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-83-7 CAPLUS
CN Benzonitrile, 3-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-5-phenoxy- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-84-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[(3'-fluoro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-85-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-86-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[4'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-87-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(2'-methoxy[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-88-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(3'-methoxy[1,1'-biphenyl]-3-yl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-90-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4'-methoxy[1,1'-biphenyl]-3-yl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-91-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(5-phenyl-3-pyridinyl)oxy]-, exo- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-92-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(2-fluoro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-93-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-methyl[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-94-0 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 3'-(8-azabicyclo[3.2.1]oct-3-yloxy)-2'-fluoro- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-95-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-98-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-methyl[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939788-99-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[6-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-00-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-fluoro-5-(4-pyridinyl)phenoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-01-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-chloro-5-(4-pyridinyl)phenoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-02-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-chloro-3-(3-pyridinyloxy)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-03-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-methyl-3-(4-pyridinyl)phenoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-04-5 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarbonitrile, 5-(8-azabicyclo[3.2.1]oct-3-yloxy)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-05-6 CAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 3'-(8-azabicyclo[3.2.1]oct-3-yloxy)-5'-chloro- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-06-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-chloro-6-phenyl-2-pyridinyl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-07-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4,6-diphenyl-2-pyridinyl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-08-9 CAPLUS
CN Benzonitrile, 4-[6-(8-azabicyclo[3.2.1]oct-3-yloxy)-4-chloro-2-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-09-0 CAPLUS
CN Benzonitrile, 4-[2-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-chloro-4-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-10-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(4-pyridinyl)phenoxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-11-4 CAPLUS
CN Benzonitrile, 4-[6-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-2-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-12-5 CAPLUS
CN Benzonitrile, 2-[4-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-chloro-2-pyridinyl]-
(CA INDEX NAME)

Relative stereochemistry.



RN 939789-13-6 CAPLUS
CN Benzonitrile, 2-[6-(8-azabicyclo[3.2.1]oct-3-yloxy)-4-chloro-2-pyridinyl]-
(CA INDEX NAME)

Relative stereochemistry.



RN 939789-14-7 CAPLUS
CN Benzamide, 2-[6-(8-azabicyclo[3.2.1]oct-3-yloxy)-4-chloro-2-pyridinyl]-
(CA INDEX NAME)

Relative stereochemistry.



RN 939789-15-8 CAPLUS
CN Benzonitrile, 2-[2-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-chloro-4-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-16-9 CAPLUS
CN Benzonitrile, 2-[6-(8-azabicyclo[3.2.1]oct-3-yloxy)-2-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-17-0 CAPLUS
CN Benzonitrile, 4-[2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-4-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-18-1 CAPLUS
CN Benzonitrile, 4-[4-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-2-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-19-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4,5-difluoro[1,1'-biphenyl]-3-yl)oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-20-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[5-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-21-6 CAPLUS
CN 4-Pyridinecarbonitrile, 2-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-phenyl- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-22-7 CAPLUS
CN 4-Pyridinecarbonitrile, 2-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-(4-cyanophenyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-23-8 CAPLUS
CN 4-Pyridinecarbonitrile, 2-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-(2-cyanophenyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-24-9 CAPLUS
CN 4-Pyridinecarbonitrile, 2-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-25-0 CAPLUS
CN 4-Pyridinecarbonitrile, 2-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-(2-methoxyphenyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-26-1 CAPLUS
CN Benzoic acid, 2-[6-(8-azabicyclo[3.2.1]oct-3-yloxy)-4-chloro-2-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-27-2 CAPLUS
CN 4-Pyridinecarbonitrile, 2-(8-azabicyclo[3.2.1]oct-3-yloxy)-6-(3-fluorophenyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-28-3 CAPLUS
CN Benzonitrile, 3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-(3-fluoro-2-pyridinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-29-4 CAPLUS
CN Benzonitrile, 3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-(3-chloro-2-pyridinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-30-7 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-cyanophenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-31-8 CAPLUS
CN Benzonitrile, 3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-[3-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-32-9 CAPLUS
CN Benzonitrile, 3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-(2-pyridinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-33-0 CAPLUS
CN Benzonitrile, 3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-(3,5-dichloro-2-pyridinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-34-1 CAPLUS
CN Benzonitrile, 3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-(3-methoxy-2-pyridinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-35-2 CAPLUS
CN Acetamide, N-[2-[3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-cyanophenyl]-3-pyridinyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-36-3 CAPLUS
CN 3-Pyridinecarbonitrile, 2-[3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-cyanophenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-37-4 CAPLUS
CN Benzonitrile, 3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-(2-pyrimidinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-38-5 CAPLUS
CN Benzonitrile, 3-(8-azabicyclo[3.2.1]oct-3-yloxy)-5-(5-pyrimidinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-39-6 CAPLUS
CN Benzonitrile, 3-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-5-(1-isoquinolinyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-40-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(5-chloro-6-phenoxy-2-pyridinyl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939789-41-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-phenoxy-2-pyridinyl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 939960-38-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(3-phenoxyphenoxy)-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:538411 CAPLUS
DOCUMENT NUMBER: 146:514790
TITLE: 8-azabicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter reuptake inhibitors
INVENTOR(S): Peters, Dan; Eriksen, Birgitte L.; Nielsen, Elsebet Oestergaard; Redrobe, John Paul; Olsen, Gunnar M.
PATENT ASSIGNEE(S): Neurosearch A/S, Den.
SOURCE: PCT Int. Appl., 22pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007054531	A1	20070518	WO 2006-EP68275	20061109

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: DK 2005-1565 A 20051111
US 2005-736330P P 20051115
OTHER SOURCE(S): MARPAT 146:514790

AB The invention discloses 8-aza-bicyclo[3.2.1]octane derivs. useful as monoamine neurotransmitter reuptake inhibitors. The invention also discloses the use of these compds. in a method for therapy, as well as pharmaceutical compns. comprising these compds. Compound preparation is included.

IT 936701-50-7 936701-50-7D, isomers and salts
936701-51-8 936701-51-8D, isomers and salts
936701-52-9 936701-52-9D, isomers and salts
936701-53-0 936701-53-0D, isomers and salts
936701-54-1 936701-54-1D, isomers and salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(azabicyclooctane derivative monoamine neurotransmitter reuptake inhibitors)

RN 936701-50-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-methoxy-2-naphthalenyl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 936701-50-7 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[(6-methoxy-2-naphthalenyl)oxy]-, (3-exo)-
(CA INDEX NAME)

Relative stereochemistry.



RN 936701-51-8 CAPLUS
CN 2-Naphthalenol, 6-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]- (CA INDEX
NAME)

Relative stereochemistry.



RN 936701-51-8 CAPLUS
CN 2-Naphthalenol, 6-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]- (CA INDEX
NAME)

Relative stereochemistry.



RN 936701-52-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-ethoxy-2-naphthalenyl)oxy]-, (3-exo)-
(CA INDEX NAME)

Relative stereochemistry.



RN 936701-52-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-ethoxy-2-naphthalenyl)oxy]-, (3-exo)-
(CA INDEX NAME)

Relative stereochemistry.



RN 936701-53-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[6-(1-methylethoxy)-2-naphthalenyl]oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 936701-53-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[6-(1-methylethoxy)-2-naphthalenyl]oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 936701-54-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(7-methoxy-2-naphthalenyl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 936701-54-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(7-methoxy-2-naphthalenyl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



IT 936701-59-6P 936701-60-9P 936701-61-0P
936701-62-1P 936701-63-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(azabicyclooctane derivative monoamine neurotransmitter reuptake inhibitors)
RN 936701-59-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-methoxy-2-naphthalenyl)oxy]-, hydrochloride (1:1), (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 936701-60-9 CAPLUS
CN 2-Naphthalenol, 6-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 936701-61-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-ethoxy-2-naphthalenyl)oxy]-, hydrochloride (1:1), (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 936701-62-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[6-(1-methylethoxy)-2-naphthalenyl]oxy]-, hydrochloride (1:1), (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 936701-63-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(7-methoxy-2-naphthalenyl)oxy]-, hydrochloride (1:1), (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:405401 CAPLUS
DOCUMENT NUMBER: 146:421857
TITLE: Preparation of bridged cyclic amine compounds as pest control agents
INVENTOR(S): Hamamoto, Isami; Takahashi, Jun; Yano, Makio; Kawaguchi, Masahiro; Hanai, Daisuke; Iwasa, Takao
PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan
SOURCE: PCT Int. Appl., 98pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007040282	A1	20070412	WO 2006-JP320133	20061006

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

JP 2005-294126	A	20051006
JP 2005-294127	A	20051006
JP 2005-297803	A	20051012
JP 2005-297804	A	20051012
JP 2006-16877	A	20060125
JP 2006-182314	A	20060630

OTHER SOURCE(S): MARPAT 146:421857
GI



I



II

AB Title compds. I [Cy1 = (un)substituted aromatic ring; X = oxygen, sulfur, (un)substituted nitrogen, etc.; R1a and R2a, R1a and R4a, R2a and R3a, or R3a and R4a may combine to form a saturated ring.; R1a-R4a, R1b-R4b and R5 = H, hydroxy, halo, etc.; Cy2 = (un)substituted aromatic ring; when R1a and R2a may combine to form saturated ring and Cy1 is a (un)substituted Ph, Cy2 is a (un)substituted aromatic heterocycle.; when Cy1 is a (un)substituted Ph and Cy2 is a pyridin-2-yl, Cy2 is a pyridin-2-yl substituted with one or more cyano groups.], salts or N-oxides thereof were prepared For example, reaction of tropine with 2-chloro-5-trifluoromethylpyridine followed by treatment with 2,2,2-trichloroethyl chloroformate, reduction using Zn/acetic acid and O-arylation with 2-fluoro-5-trifluoromethylbenzaldehyde afforded compound II [R = CHO; R' = CF3]. Compound II [R = OCH2CH2CH3; R' = CF3] controlled two-spotted spider mite by 100%.

IT 866615-17-0P 934182-68-0P 934216-25-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bridged cyclic amine compds. as pest control agents)

RN 866615-17-0 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[2-propoxy-4-(trifluoromethyl)phenoxy]-, hydrochloride (1:1), (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 934182-68-0 CAPLUS

CN Benzoic acid, 2-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yloxy]-5-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 934216-25-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1097510 CAPLUS
DOCUMENT NUMBER: 145:438420
TITLE: Preparation of N-[[(ureido)phenoxy]hetero/aryl]benzamides and related derivatives as NPY antagonists and their use for treating obesity, and abnormal food behavior and for controlling food intake
INVENTOR(S): Botez, Iuliana; David-Basei, Christelle; Gourlaoueen, Nelly; Nicolaie, Eric; Balavoine, Fabrice; Valette, Gerard; Serradeil-Le Gal, Claudine
PATENT ASSIGNEE(S): Cerep, Fr.
SOURCE: PCT Int. Appl., 430pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006108965	A2	20061019	WO 2006-FR829	20060414
WO 2006108965	A3	20070329		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
FR 2884516	A1	20061020	FR 2005-3795	20050415
FR 2884516	B1	20070622		
AU 2006234413	A1	20061019	AU 2006-234413	20060414
CA 2604773	A1	20061019	CA 2006-2604773	20060414
EP 1879887	A2	20080123	EP 2006-743700	20060414
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
KR 2008009112	A	20080124	KR 2007-726216	20071112

PRIORITY APPLN. INFO.: FR 2005-3795 A 20050415
WO 2006-FR829 W 20060414

OTHER SOURCE(S): MARPAT 145:438420
GI



II



III

AB Title compds. R8R9N-L3-A-Ar3(R5R6)-L2-Ar2(R3R4)-L1-Ar1(R1R2)-Z-C(:Y)-X [I; X = di/alkylamino, hydrazino; Z = O, NH; Ar1 = Ph; Y = O, S; or Y = N, in which case Y, Z, and the Ph to which Z is attached form a benzimidazole or benzoxazole ring; R1, R2 = independently H, halo, OH, etc.; L1 = O, S, alkylene; Ar2 = hetero/aryl, heterocyclyl; R3 = independently H, halo, OH, CF3, OCF3, etc.; R1R2Ar1L1Ar2 = tricycle in which R1R3 = alkylene, L1 = O, S, and Ar2 = Ph; L2 = CONH and derivs., CH2O, OCH2, a bond with provisos; Ar3 = hetero/aryl, heterocyclyl; when L2 = a bond, Ar3 and Ar2 cannot be simultaneously heteroaryl or heterocyclyl; R5, R6 = independently H, halo, OH, alkyl, etc.; A = a bond, O, alkyl(id)ene, CONH, etc. L3 = (un)substituted cyclo/alkylene, bicyclo or polycycloalkyl(id)ene, etc. with proviso; or L3AAr3 = O heterocycle; R8, R9 = independently H, NH2, alkoxy/cyclo/alkyl, heterocyclyl, etc.; or NR8R9 = mono or poylcyclic N heterocycle; including quaternary ammonium compds. containing N+R8R9R10; R10 = alkyl; with provisos; and their pharmaceutically acceptable salts, solvates and hydrates, optical and geometrical isomers and their mixts.] were prepared as neuropeptide Y (NPY) antagonists, particularly selective NPY Y1 subtype antagonists, and their use in therapeutic or prophylactic treatment all NPY involving disorders. Pharmaceutical compns. comprising I and treating methods using them are also disclosed. Thus, II, isolated as HCl salt, was prepared by reacting tropine with 4-fluorobenzonitrile, followed by nitrile hydrolysis, activation of the acid in the presence of TBTU/HOBT in DMF, and reaction with 1-[4-(4-aminophenoxy)-3-ethoxyphenyl]-3-(1-ethylpropyl)urea. III bound specifically to NPY Y1 receptor (IC50 for neuropeptide Y1, Y2, Y4, and Y5 receptors = 1.80 nM, > 10,000 nM, 2620 NM, and > 10,000 nM, resp.). In a test measuring the effects of III on arterial hypertension induced by [Leu31,Pro34]NPY in anesthetized rats, 3 mg/kg III administered orally reduced the blood pressure by .apprx.10 mm Hg after 1.5 h. I are useful for treating diseases characterized by elevated neuropeptide Y activity such as obesity, and abnormal food behavior, and for controlling food intake.

IT 912945-09-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of NPY antagonists and their use for treating obesity, and abnormal food behavior and for controlling food intake)

RN 912945-09-6 CAPLUS

CN Benzamide, 4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yloxy]-N-[4-[4-[[[(1-ethylpropyl)amino]carbonyl]amino]-2-methoxyphenoxy]phenyl]- (CA INDEX NAME)

Relative stereochemistry.



IT 912945-10-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of NPY antagonists and their use for treating obesity, and abnormal food behavior and for controlling food intake)

RN 912945-10-9 CAPLUS

CN Benzamide, 4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yloxy]-N-[4-[4-[[[(1-ethylpropyl)amino]carbonyl]amino]-2-methoxyphenoxy]phenyl]-N-(2-methoxyethyl)- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B

IT 912947-05-8P 912949-97-4P 912950-24-4P
912950-28-8P 912963-22-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of NPY antagonists and their use for treating obesity, and abnormal food behavior and for controlling food intake)

RN 912947-05-8 CAPLUS
CN Benzamide, 4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yloxy]-N-[4-[4-[[[(1-ethylpropyl)amino]carbonyl]amino]-2-methoxyphenoxy]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 912945-09-6
CMF C33 H40 N4 O5

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 912949-97-4 CAPLUS
CN Benzoic acid, 4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yloxy]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 912950-24-4 CAPLUS
CN Benzamide, 4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yloxy]-N-[4-(2-methoxy-4-nitrophenoxy)phenyl]-N-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 912950-28-8 CAPLUS
CN Benzamide, 4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yloxy]-N-[4-(2-methoxy-4-nitrophenoxy)phenyl]-N-propyl- (CA INDEX NAME)

Relative stereochemistry.



RN 912963-22-5 CAPLUS
CN Benzonitrile, 4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yloxy]- (CA INDEX NAME)

Relative stereochemistry.



IT 912951-38-3, 4-[(8-Azabicyclo[3.2.1]oct-3-yl)oxy]-N-[4-[4-[3-(1-ethylpropyl)ureido]-2-methoxyphenoxy]phenyl]benzamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of NPY antagonists and their use for treating obesity, and abnormal food behavior and for controlling food intake)

RN 912951-38-3 CAPLUS

CN Benzamide, 4-(8-azabicyclo[3.2.1]oct-3-yloxy)-N-[4-[4-[[[(1-ethylpropyl)amino]carbonyl]amino]-2-methoxyphenoxy]phenyl]- (CA INDEX NAME)



L4 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:700029 CAPLUS
DOCUMENT NUMBER: 145:167108
TITLE: Preparation of novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
INVENTOR(S): Peters, Dan; Dahl, Bjarne H.; Olsen, Gunnar M.; Nielsen, Elsebet Oestergaard; Scheel-Krueger, Joergen; Redrobe, John Paul
PATENT ASSIGNEE(S): Neurosearch A/S, Den.
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006075004	A2	20060720	WO 2006-EP50143	20060111
WO 2006075004	A3	20061026		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1838705	A2	20071003	EP 2006-703575	20060111
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2008004252	A1	20080103	US 2007-794365	20070628
PRIORITY APPLN. INFO.:			DK 2005-68	A 20050113
			US 2005-643590P	P 20050114
			WO 2006-EP50143	W 20060111

OTHER SOURCE(S): MARPAT 145:167108
GI



I

AB The title compds. I [R1 = CH2CO2Et, CH2CONH2, CH2(pyridinyl), etc.; X = O, S, NR3; R3 = H, alkyl, C(O)R4, SO2R4' R4 = H, alkyl; R2 = (un)substituted (hetero)aryl], useful as monoamine neurotransmitter re-uptake inhibitors, were prepared Thus, reacting 3-(3,4-dichlorophenoxy)-8-aza-bicyclo[3.2.1]octane with Et bromoacetate afforded 94% Et [3-(3,4-dichlorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]acetate. Preferred compds. I show a biol. activity in the submicromolar and micromolar range,

i.e. of from below 1 to about 100 μM. The invention also relates to the use of compds. I in a method for therapy and to pharmaceutical compns. comprising the compds. I.

IT 900501-97-5 900501-98-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of novel azabicyclo[3.2.1]octane derivs. as monoamine neurotransmitter reuptake inhibitors useful for therapy)

RN 900501-97-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(3,4-dichlorophenoxy)- (CA INDEX NAME)



RN 900501-98-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(5-chloro-2-pyridinyl)oxy]- (CA INDEX NAME)



L4 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:317352 CAPLUS
DOCUMENT NUMBER: 144:350546
TITLE: Chromen-2-one derivatives as monoamine neurotransmitter re-uptake inhibitors, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Peters, Dan; Olsen, Gunnar M.; Scheel-Krueger, Joergen; Nielsen, Elsebet Oestergaard
PATENT ASSIGNEE(S): Neurosearch A/S, Den.
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2006035034	A1	20060406	WO 2005-EP54861		20050928
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
AU 2005288914	A1	20060406	AU 2005-288914		20050928
CA 2582297	A1	20060406	CA 2005-2582297		20050928
EP 1797088	A1	20070620	EP 2005-792113		20050928
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR					
CN 101023081	A	20070822	CN 2005-80031765		20050928
MX 200702384	A	20070511	MX 2007-2384		20070227
US 2007232666	A1	20071004	US 2007-661966		20070306
KR 2007061846	A	20070614	KR 2007-707237		20070329
IN 2007CN01309	A	20070831	IN 2007-CN1309		20070329
NO 2007002209	A	20070427	NO 2007-2209		20070427
PRIORITY APPLN. INFO.:			DK 2004-1491	A	20040930
			US 2004-614052P	P	20040930
			WO 2005-EP54861	W	20050928

OTHER SOURCE(S): MARPAT 144:350546
GI



I



II



III

AB The invention relates to chromen-2-one derivs. I, which are monoamine neurotransmitter re-uptake inhibitors. In compds. I, R1 is H or (un)substituted alkyl; R2, R3, R4, and R5 are each independently selected from H and alkyl, or R2 and R4 together form -(CH2)p-, where p is 1-3; m is 0-2; n is 0-2; X is O or (un)substituted N; and Q represents (un)substituted chromen-2-one; including isomers and pharmaceutically acceptable salts thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a therapeutically effective amount of a compound I with at least one pharmaceutically acceptable carrier, excipient or diluent, as well as to the use of the compns. for the treatment, prevention, or alleviation of a disease, disorder, or condition responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system. Mitsunobu reaction of tropine (II) with 7-hydroxycoumarine gave chromenone III. Preferred compds. of the invention express activity from below 1 μM to about 100 μM.

IT 881387-70-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of chromenone derivs. as monoamine neurotransmitter re-uptake inhibitors)

RN 881387-70-8 CAPLUS

CN 2H-1-Benzopyran-2-one, 6-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]- (CA INDEX NAME)

Relative stereochemistry.



IT 881387-66-2P 881387-68-4P 881387-69-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of chromenone derivs. as monoamine neurotransmitter re-uptake inhibitors)
RN 881387-66-2 CAPLUS
CN 2H-1-Benzopyran-2-one, 7-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 881387-68-4 CAPLUS
CN 2H-1-Benzopyran-2-one, 7-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 881387-69-5 CAPLUS
CN 2H-1-Benzopyran-2-one, 6-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1103769 CAPLUS
DOCUMENT NUMBER: 143:386926
TITLE: Preparation of N-(2-pyridyl)cyclic amine derivatives as pest control agents
INVENTOR(S): Hamamoto, Isami; Takahashi, Jun; Yano, Makio; Hanai, Daisuke; Iwasa, Takao
PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan
SOURCE: PCT Int. Appl., 183 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095380	A1	20051013	WO 2005-JP6887	20050330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005228289	A1	20051013	AU 2005-228289	20050330
AU 2005228289	B2	20080110		
EP 1731518	A1	20061213	EP 2005-728646	20050330
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1938292	A	20070328	CN 2005-80009934	20050330
BR 2005009292	A	20070918	BR 2005-9292	20050330
IN 2006KN02652	A	20070601	IN 2006-KN2652	20060913
US 2008045569	A1	20080221	US 2006-599388	20060927
KR 2007021174	A	20070222	KR 2006-720773	20061004
KR 804452	B1	20080220		

PRIORITY APPLN. INFO.: JP 2004-106668 A 20040331
JP 2004-374007 A 20041224
WO 2005-JP6887 W 20050330
OTHER SOURCE(S): MARPAT 143:386926
GI



I

AB The title compds. (I) [R1 = HO, halo, cyano, NO2, CHO, each (un)substituted C1-6 alkyl, C1-6 alkoxy, NH2, or 5- or 6-membered heterocyclyl containing at least one heteroatom selected from O, N, and S,

C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkenyl, C1-6 alkylcarbonyl, C1-6 haloalkoxy, C2-6 alkenyloxy, C2-6 haloalkenyloxy, C2-6 alkynyloxy, C1-6 alkylcarbonyloxy, C1-6 alkoxycarbonyloxy, C1-6 alkylthiocarbonyloxy, C1-6 alkylthio, C1-6 haloalkylthio, C1-6 alkylsulfinyl, C1-6 haloalkylsulfinyl, C1-6 alkylsulfonyl, etc.; m = 0-5; R2 = halo, NO2, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, (un)substituted 5- or 6-membered heterocyclyl containing at least one heteroatom selected from O, N, and S; k = 0-4; R3, R31 R4, R41, R5, R51, R6, R61, R7 = H, C1-6 alkyl, C1-6 alkoxycarbonyl, C1-6 alkoxy; or R3 and R4 or R5 and R6 together form a saturated ring; X = O, S, S(O), S(O)2;n = 0, 1], salts, or N-oxide thereof are prepared Thus, a solution of 3.0 g 4-hydroxypiperidine and 5.4 g 2-chloro-5-trifluoromethylpyridine in 25 mL ethanol was treated with 4.5 g Et3N and refluxed overnight to give 5.98 g 1-[5-(Trifluoromethyl)pyridin-2-yl]piperidin-4-ol (II). A solution of II 4.9, 5-hydroxy-2-nitrobenzotrifluoride 3.2, and Ph3P 5.6 g in 30 mL THF was treated dropwise with a solution of 4.3 g diisopropyl azodicarboxylate in 30 mL THF under ice-cooling, warmed to room temperature, and stirred for 3 h to give 5.98 g 4-[4-Nitro-3-(trifluoromethyl)phenoxy]-1-[5-(trifluoromethyl)-2-pyridyl]-piperidine (III). A solution of 5.7 g III in 300 mL ethanol was treated with 18.8 g zinc powder and 1.9 g CaCl2.2H2O and refluxed overnight to give 5.4 g 4-[4-Amino-3-(trifluoromethyl)phenoxy]-1-[5-(trifluoromethyl)-2-pyridyl]-piperidine (IV). IV at 125 ppm controlled 100% adult Tetranychus urticae on kidney bean leaf.

IT 866615-17-0P 866615-33-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(2-pyridyl)cyclic amine derivs. as pesticides such as insecticides and miticides)

RN 866615-17-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[2-propoxy-4-(trifluoromethyl)phenoxy]-, hydrochloride (1:1), (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 866615-33-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[2-propoxy-4-(trifluoromethyl)phenoxy]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:141056 CAPLUS
DOCUMENT NUMBER: 142:240467
TITLE: Piperidinyl- and piperazinyl-substituted phenylsulfonyl benzazepine compounds as antipsychotic agents and their preparation, pharmaceutical compositions, and use.
INVENTOR(S): Cooper, David Gwyn; Forbes, Ian Thomson; Garzya, Vincenzo; Gribble, Andrew Derrick; Lightfoot, Andrew P.; Payne, Andrew H.; Walker, Graham
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014578	A1	20050217	WO 2004-EP8965	20040805

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	GB 2003-18707	A	20030808
	GB 2003-18715	A	20030808

OTHER SOURCE(S): CASREACT 142:240467; MARPAT 142:240467
GI



I



II

AB The invention provides compds. I [wherein: A, B = (CH2)m and (CH2)n, resp.; R1 = H or C1-6 alkyl; R2 = H, halo, OH, cyano, NO2, hydroxyalkyl, CF3, CF3O, C1-6 alkyl, C1-6 alkoxy, C1-6 fluoroalkoxy, (CH2)p-C3-6-cycloalkyl, (CH2)pO-C3-6-cycloalkyl, CO-C1-6-alkyl, SO2-C1-6-alkyl, SO-C1-6-alkyl, S-C1-6-alkyl, CO2-C1-6-alkyl, CO2NR5R6, SO2NR5R6, (CH2)pNR5R6, (CH2)pNR5COR6, (un)substituted (hetero)aryl or heterocyclyl; R3 = (un)substituted (hetero)aryl; R4 = H, OH, C1-6 alkyl, C1-6 alkoxy, CF3, CF3O, halo, OSO2CF3, (CH2)p-C3-6-cycloalkyl, (CH2)qO-C1-6-alkyl, or (CH2)pO-C3-6-cycloalkyl; X = CH or N; Z = bond, O, (CH2)r, CH2O, OCH2, or CO; R5, R6 = H, C1-6 alkyl, or together with the intervening atoms form an azacycloalkyl ring with optional oxo substitution; R7, R8 = H or C1-6 alkyl; or R7R8 = (CH2)s; m, n = 1 or 2; p = 0, 1, 2, or 3; q, r = 1, 2, or 3; s = 2, 3, or 4; or a pharmaceutically acceptable salt or solvate, with the proviso that when X = N, then Z = bond, (CH2)r, or CO]. I are useful in therapy, in particular as antipsychotic agents. Use of I for treatment of numerous other CNS diseases and disorders is also claimed. Approx. 60 compds. were prepared in examples, and a subset of these are claimed individually. For instance, the intermediate 7-(4-fluorobenzenesulfonyl)-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (prepared in 5 steps) underwent aromatic amination with 4-(4-fluorophenoxy)piperidine in dry DMSO at 30° to give 53% invention compound II. Compound II bound to human or unspecified cloned receptors in vitro with Ki values as follows: human D3 7.2-8.8, human D2 6.6-8.5, cloned 5-HT6 7.2-8.5, cloned 5-HT2C 6.6-8.2, and cloned 5-HT2A 7.3-9.2.

IT 845291-48-7P, endo-3-(4-Chlorophenoxy)-8-azabicyclo[3.2.1]octane
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of piperidinyl- and piperazinyl-substituted phenylsulfonyl benzazepine compds. as antipsychotics)

RN 845291-48-7 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-(4-chlorophenoxy)-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1154707 CAPLUS
DOCUMENT NUMBER: 142:94018
TITLE: Preparation of novel 8-azabicyclo[3.2.1]octane derivatives for use in pharmaceutical compositions as monoamine neurotransmitter re-uptake inhibitors
INVENTOR(S): Peters, Dan; Eriksen, Birgitte L.; Nielsen, Elsebet Ostergaard; Scheel-Krueger, Jorgen; Olsen, Gunnar M.
PATENT ASSIGNEE(S): Neurosearch A/S, Den.
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113334	A1	20041229	WO 2004-EP51167	20040618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249441	A1	20041229	AU 2004-249441	20040618
CA 2530023	A1	20041229	CA 2004-2530023	20040618
EP 1638965	A1	20060329	EP 2004-741837	20040618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1798745	A	20060705	CN 2004-80015575	20040618
BR 2004011608	A	20060808	BR 2004-11608	20040618
MX 2005PA13444	A	20060731	MX 2005-PA13444	20051209
US 2006142331	A1	20060629	US 2005-561417	20051219
IN 2005CN03509	A	20070518	IN 2005-CN3509	20051223
NO 2006000360	A	20060324	NO 2006-360	20060123

PRIORITY APPLN. INFO.:	DK 2003-939	A	20030624
	US 2003-482566P	P	20030626
	DK 2003-1487	A	20031009
	US 2003-509808P	P	20031010
	DK 2004-228	A	20040213
	US 2004-544210P	P	20040213
	WO 2004-EP51167	W	20040618

OTHER SOURCE(S): MARPAT 142:94018
GI



I



II

AB 8-Azabicyclo[3.2.1]octane derivs. of tropine and pseudotropine, such as I [R = H, alkyl; R1 = aryl, heteroaryl; X = O, S, NR3; R3 = H, alkyl, acyl, sulfonyl, etc.], were prepared for therapeutic use in the treatment of diseases, disorders or conditions responsive to inhibition of monoamine neurotransmitter reuptake in the central nervous system (CNS). The CNS disorders claimed for treatment include mood disorder, depression, atypical depression, major depressive disorder, dysthymic disorder, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, mood disorder due to a general medical condition, substance-induced mood disorder, pseudodementia, Ganser's syndrome, obsessive compulsive disorder, panic disorder, panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, panic attack, memory deficits, memory loss, attention deficit hyperactivity disorder, obesity, anxiety, generalized anxiety disorder, eating disorder, Parkinson's disease, parkinsonism, dementia, dementia of ageing, senile dementia, Alzheimer's disease, acquired immunodeficiency syndrome dementia complex, memory dysfunction in ageing, specific phobia, social phobia, posttraumatic stress disorder, acute stress disorder, drug addiction, drug misuse, cocaine abuse, nicotine abuse, tobacco abuse and alcoholism. Further, the CNS disorders claimed for treatment include pain, chronic pain, inflammatory pain, neuropathic pain, migraine pain, tension-type headache, chronic tension-type headache, pain associated with depression, fibromyalgia, arthritis, osteoarthritis, rheumatoid arthritis, back pain, cancer pain, irritable bowel pain, irritable bowel syndrome, postoperative pain, post-stroke pain, drug-induced neuropathy, diabetic neuropathy, sympathetically-maintained pain, trigeminal neuralgia, dental pain, myofacial pain, phantom-limb pain, bulimia, premenstrual syndrome, late luteal phase syndrome, posttraumatic syndrome, chronic fatigue syndrome, urinary incontinence, stress incontinence, urge incontinence, nocturnal incontinence, sexual dysfunction, premature ejaculation, erectile difficulty, erectile dysfunction, eating disorders, anorexia nervosa, sleep disorders, autism, mutism, trichotillomania, narcolepsy, post-stroke depression, stroke-induced brain damage, stroke-induced neuronal damage or Gilles de la Tourette's disease. Thus, endo-8-azabicyclo[3.2.1]octane derivative II was prepared in 33% yield by reacting tropine with tetrahydrothiophene using t-BuOK and 18-crown-6 ether in DMF. Dosages and pharmaceutical compns. of these 8-azabicyclo[3.2.1]octanes were discussed.

IT 817198-27-9P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of novel 8-azabicyclo[3.2.1]octane tropine or pseudotropine derivs. for use in pharmaceutical compns. as monoamine neurotransmitter re-uptake inhibitors)

RN 817198-27-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-(3,4-dichlorophenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



IT 817194-14-2P 817194-20-0P 817194-28-8P
817194-43-7P 817194-49-3P, exo-3-(3-Chlorophenoxy)-8H-8-azabicyclo[3.2.1]octane 817194-50-6P 817194-55-1P
817194-59-5P, exo-3-(4-Chlorophenoxy)-8H-8-azabicyclo[3.2.1]octane
817194-60-8P 817194-64-2P, exo-3-(2-Chloro-3-trifluoromethylphenoxy)-8H-8-azabicyclo[3.2.1]octane 817194-65-3P
817194-71-1P 817194-76-6P 817194-96-0P,
exo-3-(4-Chloro-3-trifluoromethylphenoxy)-8H-8-azabicyclo[3.2.1]octane
817194-97-1P 817195-02-1P, exo-3-(2-Dibenzofuranyloxy)-8H-8-azabicyclo[3.2.1]octane 817195-03-2P 817195-08-7P
, exo-3-(1-Naphthyloxy)-8H-8-azabicyclo[3.2.1]octane 817195-09-8P
817195-12-3P, exo-3-(2-Naphthyloxy)-8H-8-azabicyclo[3.2.1]octane
817195-13-4P 817195-17-8P, exo-3-(3-Chloro-4-cyanophenoxy)-8H-8-azabicyclo[3.2.1]octane 817195-18-9P
817195-20-3P, exo-3-(4-Chloro-3-methylphenoxy)-8H-8-azabicyclo[3.2.1]octane 817195-21-4P 817195-24-7P,
exo-3-(4-Chloronaphthalen-1-yloxy)-8H-8-azabicyclo[3.2.1]octane
817195-25-8P 817195-28-1P, exo-3-(Quinolin-2-yloxy)-8H-8-azabicyclo[3.2.1]octane 817195-29-2P 817195-34-9P,
exo-3-(5-Chloropyridin-2-yl)-8H-8-azabicyclo[3.2.1]octane
817195-35-0P 817195-41-8P, exo-3-(4-Methoxyphenoxy)-8H-8-azabicyclo[3.2]octane 817195-42-9P 817195-46-3P,
exo-3-(Isoquinolin-5-yloxy)-8H-8-azabicyclo[3.2.1]octane
817195-47-4P 817195-52-1P 817195-57-6P,
exo-3-(4-Bromo-3-chlorophenoxy)-8H-8-azabicyclo[3.2.1]octane
817195-58-7P 817195-65-6P, exo-3-(Quinolin-6-yloxy)-8H-8-azabicyclo[3.2.1]octane 817195-66-7P 817195-78-1P,
exo-3-(4-Cyanophenoxy)-8H-8-azabicyclo[3.2.1]octane 817195-79-2P
817195-85-0P, exo-3-(Quinolin-8-yloxy)-8H-8-azabicyclo[3.2.1]octane 817195-86-1P 817195-88-3P,
exo-3-(4-Methylphenoxy)-8H-8-azabicyclo[3.2.1]octane 817195-89-4P
817195-95-2P, exo-3-(6-Chloropyridin-2-yloxy)-8H-8-azabicyclo[3.2.1]octane 817195-96-3P 817196-01-3P,
exo-3-(5-Bromopyridin-2-yloxy)-8H-8-azabicyclo[3.2.1]octane
817196-02-4P 817196-04-6P, exo-3-(6-Bromopyridin-2-yloxy)-8H-8-azabicyclo[3.2.1]octane 817196-05-7P
817196-09-1P, exo-3-(Isoquinolin-1-yloxy)-8H-8-azabicyclo[3.2.1]octane 817196-10-4P 817196-13-7P
817196-18-2P 817196-23-9P, exo-3-(6-Methoxypyridin-2-yloxy)-8H-8-azabicyclo[3.2.1]octane 817196-24-0P
817196-30-8P, exo-3-(5-Trifluoromethylpyridin-2-yloxy)-8H-8-azabicyclo[3.2.1]octane 817196-31-9P 817196-36-4P,
exo-3-(6-Ethoxypyridin-2-yloxy)-8H-8-azabicyclo[3.2.1]octane
817196-37-5P 817196-44-4P, exo-3-(4-Fluoro-3-trifluoromethylphenoxy)-8H-8-azabicyclo[3.2.1]octane 817196-45-5P
817199-45-4P 817629-76-8P 817629-77-9P
817629-78-0P 817629-89-3P 817629-91-7P
817629-92-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological

study); PREP (Preparation); USES (Uses)
(preparation of novel 8-azabicyclo[3.2.1]octane tropine or pseudotropine derivs. for use in pharmaceutical compns. as monoamine neurotransmitter re-uptake inhibitors)

RN 817194-14-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(3,4,5-trichloro-2-thienyl)oxy]-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817194-20-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(2,3-dichlorophenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817194-28-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(3,4-dichlorophenoxy)-, hydrochloride, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 817194-43-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(3-chloro-4-fluorophenoxy)-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817194-42-6
CMF C13 H15 Cl F N O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817194-49-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(3-chlorophenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817194-50-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(3-chlorophenoxy)-, (3-exo)-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817194-49-3
CMF C13 H16 Cl N O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817194-55-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-chloro-3-fluorophenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817194-59-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-chlorophenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817194-60-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-chlorophenoxy)-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817194-59-5
CMF C13 H16 Cl N O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817194-64-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[2-chloro-3-(trifluoromethyl)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817194-65-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[2-chloro-3-(trifluoromethyl)phenoxy]-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817194-64-2
CMF C14 H15 Cl F3 N O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817194-71-1 CAPLUS
CN 9H-Fluoren-9-one, 2-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 817194-76-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(1,2-benzisothiazol-3-yloxy)-, monohydrochloride, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 817194-96-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-chloro-3-(trifluoromethyl)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817194-97-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-chloro-3-(trifluoromethyl)phenoxy]-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817194-96-0
CMF C14 H15 Cl F3 N O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817195-02-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(2-dibenzofuranyloxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817195-03-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(2-dibenzofuranyloxy)-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817195-02-1
CMF C19 H19 N O2

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817195-08-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(1-naphthalenyloxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817195-09-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(1-naphthalenyloxy)-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817195-08-7
CMF C17 H19 N O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817195-12-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-(2-naphthalenyloxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817195-13-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(2-naphthalenyloxy)-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817195-12-3
CMF C17 H19 N O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817195-17-8 CAPLUS
CN Benzonitrile, 4-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-2-chloro- (CA INDEX NAME)

Relative stereochemistry.



RN 817195-18-9 CAPLUS
CN Benzonitrile, 4-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-2-chloro-,

(2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 817195-17-8
CMF C14 H15 Cl N2 O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817195-20-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-chloro-3-methylphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817195-21-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-chloro-3-methylphenoxy)-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817195-20-3
CMF C14 H18 Cl N O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817195-24-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-chloro-1-naphthalenyl)oxy]-, (3-exo)-
(CA INDEX NAME)

Relative stereochemistry.



RN 817195-25-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(4-chloro-1-naphthalenyl)oxy]-, (3-exo)-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817195-24-7
CMF C17 H18 Cl N O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817195-28-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(2-quinolinyloxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817195-29-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(2-quinolinyloxy)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817195-28-1
CMF C16 H18 N2 O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817195-34-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(5-chloro-2-pyridinyl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817195-35-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(5-chloro-2-pyridinyl)oxy]-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817195-34-9
CMF C12 H15 Cl N2 O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817195-41-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-methoxyphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817195-42-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-methoxyphenoxy)-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817195-41-8
CMF C14 H19 N O2

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817195-46-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(5-isoquinolinyloxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817195-47-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(5-isoquinolinyloxy)-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817195-46-3
CMF C16 H18 N2 O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817195-52-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-bromo-2-naphthalenyl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817195-57-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-bromo-3-chlorophenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817195-58-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-bromo-3-chlorophenoxy)-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817195-57-6
CMF C13 H15 Br Cl N O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817195-65-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(6-quinolinyloxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817195-66-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(6-quinolinyloxy)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817195-65-6
CMF C16 H18 N2 O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817195-78-1 CAPLUS
CN Benzonitrile, 4-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]- (CA INDEX NAME)

Relative stereochemistry.



RN 817195-79-2 CAPLUS
CN Benzonitrile, 4-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yloxy]-,
(2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 817195-78-1
CMF C14 H16 N2 O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817195-85-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(8-quinolinyloxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817195-86-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(8-quinolinyloxy)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817195-85-0
CMF C16 H18 N2 O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817195-88-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-methylphenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817195-89-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-methylphenoxy)-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817195-88-3
CMF C14 H19 N O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817195-95-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-chloro-2-pyridinyl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817195-96-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-chloro-2-pyridinyl)oxy]-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817195-95-2
CMF C12 H15 Cl N2 O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817196-01-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(5-bromo-2-pyridinyl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817196-02-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(5-bromo-2-pyridinyl)oxy]-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817196-01-3
CMF C12 H15 Br N2 O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817196-04-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-bromo-2-pyridinyl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817196-05-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-bromo-2-pyridinyl)oxy]-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817196-04-6
CMF C12 H15 Br N2 O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817196-09-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(1-isoquinolinyloxy)-, (3-exo)- (CA INDEX

NAME)

Relative stereochemistry.



RN 817196-10-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(1-isoquinolinyloxy)-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817196-09-1
CMF C16 H18 N2 O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817196-13-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(trifluoromethoxy)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817196-18-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-(trifluoromethoxy)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817196-23-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-methoxy-2-pyridinyl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817196-24-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-methoxy-2-pyridinyl)oxy]-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817196-23-9
CMF C13 H18 N2 O2

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817196-30-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817196-31-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817196-30-8
CMF C13 H15 F3 N2 O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817196-36-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-ethoxy-2-pyridinyl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817196-37-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6-ethoxy-2-pyridinyl)oxy]-, (3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817196-36-4
CMF C14 H20 N2 O2

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817196-44-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-fluoro-3-(trifluoromethyl)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817196-45-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-fluoro-3-(trifluoromethyl)phenoxy]-,

(3-exo)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 817196-44-4
CMF C14 H15 F4 N O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 817199-45-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(1,2-benzisothiazol-3-yloxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817629-76-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(3,4,5-trichloro-2-thienyl)oxy]-, hydrochloride, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 817629-77-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(3,4-dichlorophenoxy)-, hydrochloride, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 817629-78-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-(trifluoromethyl)phenoxy]-, hydrochloride, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 817629-89-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(3,4,5-trichloro-2-thienyl)oxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817629-91-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(3,4-dichlorophenoxy)-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 817629-92-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-(trifluoromethyl)phenoxy]-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:80685 CAPLUS
DOCUMENT NUMBER: 140:146011
TITLE: Preparation of bicyclic piperidine derivatives as antagonists of the CCR1 chemokine receptor
INVENTOR(S): Blumberg, Laura Cook; Brown, Matthew Frank; Hayward, Matthew Merrill; Poss, Christopher Stanley
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009588	A1	20040129	WO 2003-IB3155	20030707
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492110	A1	20040129	CA 2003-2492110	20030707
AU 2003281527	A1	20040209	AU 2003-281527	20030707
BR 2003012699	A	20050426	BR 2003-12699	20030707
EP 1525201	A1	20050427	EP 2003-741007	20030707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1668614	A	20050914	CN 2003-817005	20030707
JP 2005533845	T	20051110	JP 2004-522638	20030707
US 2004063688	A1	20040401	US 2003-616843	20030708
IN 2004DN04155	A	20050401	IN 2004-DN4155	20041228
MX 2005PA00757	A	20050419	MX 2005-PA757	20050118

PRIORITY APPLN. INFO.: US 2002-397263P P 20020718
WO 2003-IB3155 W 20030707

OTHER SOURCE(S): MARPAT 140:146011
GI



I

AB The title compds. [I; a = 1-5; b = 0-4; c = 0-1; Q = alkyl; W = aryl, heteroaryl; Y = O, NH, N(alkyl); Z = O, NH, N(alkyl), N(acetyl); R1 = H, halo, CN, NO2, etc.; R2, R3 = H, alkyl, haloalkyl; R4 = alkylene, (CH2)xO(CH2)y (wherein x, y = 1-2); R5 = H, halo, alkyl, etc.; R6 = H,

halo, alkyl, etc.], useful as potent and selective inhibitors of MIP-1α(CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes), were prepared E.g., a multi-step synthesis of (trans)-5-chloro-2-{2-[3-(4-fluorophenoxy)-8-aza-bicyclo[3.2.1]oct-8-yl]-2-oxoethoxy}benzamide was given. All exemplified compds. I had IC50 of <10 μM in the chemotaxis assay. Pharmaceutical composition comprising the compound I is claimed.

IT 652148-02-2P 653600-07-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bicyclic piperidine derivs. as antagonists of the CCR1 chemokine receptor)

RN 652148-02-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-fluorophenoxy)-, (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 653600-07-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(4-fluorophenoxy)-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:964330 CAPLUS
DOCUMENT NUMBER: 138:39295
TITLE: Preparation of heterocyclic compounds as Rho-kinase inhibitors
INVENTOR(S): Imazaki, Naonori; Kitano, Masafumi; Ohashi, Naohito; Matsui, Kazuki
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Company, Limited, Japan
SOURCE: PCT Int. Appl., 425 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100833	A1	20021219	WO 2002-JP5609	20020606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002306284	A1	20021223	AU 2002-306284	20020606
EP 1403255	A1	20040331	EP 2002-733352	20020606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004138286	A1	20040715	US 2003-480526	20031212
US 7199147	B2	20070403		

PRIORITY APPLN. INFO.:	JP 2001-176826	A	20010612
	JP 2001-398992	A	20011228
	WO 2002-JP5609	W	20020606

OTHER SOURCE(S): MARPAT 138:39295
GI



I

AB The title compds. I [wherein one to four groups represented by the general formula R1-X are present and may be the same or different from each other; A is a saturated or unsatd. five-membered heterocycle; X is a single bond, N(R3), O, S, or the like; R1 is hydrogen, halogeno, nitro, carboxyl, substituted or unsubstituted alkyl, or the like; R2 is hydrogen, halogeno, nitro, carboxyl, substituted or unsubstituted alkyl, or the like; and R3 is hydrogen, substituted or unsubstituted alkyl, or the like] are prepared N-(1-Benzyl-4-piperidinyl)-1H-indazole-5-amine dihydrochloride monohydrate in vitro showed IC50 of 0.4 μL/mL against Rho-kinase.

IT 478834-96-7P, 5-(8-Azabicyclo[3.2.1]oct-3-yloxy)-1H-indazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as Rho-kinase inhibitors)

RN 478834-96-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(1H-indazol-5-yloxy)- (CA INDEX NAME)



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:180545 CAPLUS
DOCUMENT NUMBER: 128:217374
TITLE: Preparation of piperidinylbenzoxazinones as tocolytic oxytocin receptor antagonists.
INVENTOR(S): Sparks, Michelle A.; Freidinger, Roger M.; Perlow, Debra S.; Williams, Peter D.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 36 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5726172	A	19980310	US 1997-779296	19970106
PRIORITY APPLN. INFO.:			US 1997-779296	19970106
OTHER SOURCE(S):	MARPAT 128:217374			

GI



I

AB Title compds. (I; R1 = H, halo; W = CR2R3R4, azabicyclooctyl, tetrahydrofuryl, etc.; R2 = H, halo, alkyl; R3 = R2, aryl; R4 = haloalkyl, CONH2, cyano, CHMeOH, piperidinyl, etc.; R8 = H, alkoxy), were prepared Thus, 1-[1-[4-hydroxy-2-methoxybenzoyl]-piperidin-4-yl]-4H-3,1-benzoxazin-2(1H)-one in THF was treated with Ph3P and then with (S)-3-hydroxytetrahydrofuran and di-Et azodicarboxylate to give (R)-1-[1-[4-(tetrahydrofuran-3-oxy)-2-methoxybenzoyl]piperidin-4-yl]-4H-3,1-benzoxazin-2(1H)-one. In [3H]-oxytocin and [3H]-arginine vasopressin binding assays, representative I showed IC50 = 5-500 nM.

IT 194151-48-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidinylbenzoxazinones as tocolytic oxytocin receptor antagonists)

RN 194151-48-9 CAPLUS

CN Piperidine, 1-[4-(8-azabicyclo[3.2.1]oct-3-yloxy)-2-methoxybenzoyl]-4-(2-oxo-2H-3,1-benzoxazin-1(4H)-yl)-, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:499106 CAPLUS
DOCUMENT NUMBER: 127:190743
TITLE: Preparation of benzoxazinones as tocolytic oxytocin receptor antagonists
INVENTOR(S): Sparks, Michelle A.; Friedinger, Roger M.; Perlow, Debra S.; Williams, Peter D.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Sparks, Michelle A.; Friedinger, Roger M.; Perlow, Debra S.; Williams, Peter D.
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9725992	A1	19970724	WO 1997-US571		19970113
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9716989	A	19970811	AU 1997-16989		19970113
PRIORITY APPLN. INFO.:			US 1996-10034P	P	19960116
			GB 1996-5701	A	19960319
			WO 1997-US571	W	19970113

OTHER SOURCE(S): MARPAT 127:190743
GI



I



II

AB The title compds. [I; R1 = H, halo; W = CR2R3R4, CHR3Ar, etc.; R2 = H, halo, C1-5 alkyl; R3 = H, halo, C1-5 alkyl, Ar; R4 = mono-, di-, tri-halogenated C1-5 alkyl, CONH2, etc.; R8 = H, C1-5 alkoxy; Ar = Ph, CF3C6H4, naphthyl, etc.], oxytocin receptor antagonists which are useful in treating preterm labor, dysmenorrhea, stopping labor prior to cesarean

delivery, increasing fertility and embryonic survival, and controlling the timing of estrus in a farm animal, were prepared and formulated. Thus, reaction of benzoxazinone II with Ph2CHBr in the presence of Cs2CO3 in DMF afforded I [R1 = H; W = diphenylmethyl; R8 = MeO]. Representative compds. I showed IC50 of 5-500 nM against [3H]oxytocin and [3H]arginine vasopressin binding.

IT 194151-48-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzoxazinones as tocolytic oxytocin receptor antagonists)

RN 194151-48-9 CAPLUS

CN Piperidine, 1-[4-(8-azabicyclo[3.2.1]oct-3-yloxy)-2-methoxybenzoyl]-4-(2-oxo-2H-3,1-benzoxazin-1(4H)-yl)-, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:158064 CAPLUS
DOCUMENT NUMBER: 112:158064
TITLE: Preparation of 3-(pentafluorophenoxy)-8-azabicyclo[3.2.1]octanes and their use as medicaments
INVENTOR(S): Helsley, Grover Cleveland; Davis, Larry; Olsen, Gordon E.
PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals, Inc., USA
SOURCE: Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 333026	A1	19890920	EP 1989-104174	19890309
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4861889	A	19890829	US 1988-167942	19880314
DK 8901208	A	19890915	DK 1989-1208	19890313
JP 01275579	A	19891106	JP 1989-58073	19890313
US 4916139	A	19900410	US 1989-362639	19890607

PRIORITY APPLN. INFO.: US 1988-167942 A 19880314
OTHER SOURCE(S): CASREACT 112:158064; MARPAT 112:158064
GI For diagram(s), see printed CA Issue.
AB Title compds. I [(R1 = H, aryl; R2 = H, cyano, alkyl, (cycloalkyl)alkyl, arylalkyl, heteroarylalkyl, HCO, HCS, alkylcarbonyl, aminoalkyl, (alkylamino)thiocarbonyl, etc.] or their pharmaceutically acceptable salts, useful as analgesics, anticonvulsants, antihypertensives, and antidepressants, are prepared exo-I (R1 = R2 = H) (preparation given), 3-(3-chloropropyl)-6-fluoro-1,2-benzisoxazole, K2CO3, KI, and DMF were stirred for 7 h to give exo-I [R1 = H; R2 = 3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl] which was converted to the HCl salt (II). II at 50 mg/kg orally decreased arterial blood pressure in spontaneous hypertensive rat by 48 mm Hg. I were also tested for analgesic, anticonvulsant and antidepressant activity.
IT 126044-60-8P 126044-78-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as drug)
RN 126044-60-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(pentafluorophenoxy)-, hydrochloride, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 126044-78-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(pentafluorophenoxy)-, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:563495 CAPLUS
DOCUMENT NUMBER: 81:163495
ORIGINAL REFERENCE NO.: 81:25211a,25214a
TITLE: Synthesis of some N-carboxylic acid derivatives of 3-phenoxypyrrolidines, 4-phenoxypiperidines, and 3-phenoxynortropanes with muscle relaxant and anticonvulsant activities
AUTHOR(S): Boswell, Robert F., Jr.; Helsley, Grover C.; Duncan, Robert L., Jr.; Funderburk, William H.; Johnson, David N.
CORPORATE SOURCE: Res. Lab., A. H. Robins Co., Inc., Richmond, VA, USA
SOURCE: Journal of Medicinal Chemistry (1974), 17(9), 1000-8
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 81:163495
AB A series of 43 title compds. were prepared by the reaction of the appropriate 3-phenoxypyrrolidine, 4-phenoxypiperidine, or 3-phenoxynortropane intermediate with nitrourea [556-89-8], an isocyanate, disubstituted carbamoyl chloride, or by treating N-benzyl intermediates with cyanogen bromide [506-68-3] or phosgene. Anticonvulsant or muscle relaxant activities in mice and cats, were observed for several compds. 3-(M-Chlorophenoxy)-1-methylcarbamoylpyrrolidine (I) [28482-91-9] showed pronounced muscle relaxant activity comparable to mephenesin.
IT 36768-90-8P 36768-92-0P 36768-94-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 36768-90-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(trifluoromethyl)phenoxy]-, hydrochloride, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 36768-92-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(trifluoromethyl)phenoxy]-, hydrochloride, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 36768-94-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-(trifluoromethyl)phenoxy]-, hydrochloride, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

L4 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:405359 CAPLUS
DOCUMENT NUMBER: 77:5359
ORIGINAL REFERENCE NO.: 77:939a,942a
TITLE: Antispasmodic 8-carbamoyl-3-(trifluoromethylphenyloxy)nortropanes
INVENTOR(S): Helsley, Grover C.; Boswell, Robert F., Jr.
PATENT ASSIGNEE(S): A. H. Robins Co., Inc.
SOURCE: Ger. Offen., 27 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2143588	A	19720309	DE 1971-2143588	19710831
US 3657253	A	19720418	US 1970-68593	19700831
AU 7132714	A	19730301	AU 1971-32714	19710825
ES 394543	A1	19741016	ES 1971-394543	19710826
JP 51029159	B	19760824	JP 1971-64818	19710826
FR 2103643	A1	19720414	FR 1971-31359	19710830
FR 2103643	A5	19720414		
ZA 7105772	A	19720426	ZA 1971-5772	19710830
CH 534154	A	19730413	CH 1971-12695	19710830
CA 941380	A1	19740205	CA 1971-121717	19710830

PRIORITY APPLN. INFO.: US 1970-68593 A 19700831
GI For diagram(s), see printed CA Issue.
AB Eight title compds. [I, R = H2NCO, EtNHCO, MeNHCO, MeNHCS, or Me2NCO; R1 = m-CF3 or p-CF3 and their β-isomers (II)] were prepared from I or II (R = H) and RX (X = NHNO2 or Cl) or EtNCO, MeNCO, or MeNCS. I and II had antispasmodic effects in mice. Thus, 8-benzyl-3α-nortropine was added to NaH in DMF and the mixture heated at 65-70°. -FC6H4CF3 in DMF was added and the mixture refluxed 5 hr to give 68% I (R = PhCH2, R1 = m-CF3), which was hydrogenated in EtOH over Pd/C to give 92% I [R = H, R1 = m-CF3 (III)]. III was refluxed with H2NCONHNO2 in EtOH for 15 min to give 62% I (R = H2NCO, R1 = m-CF3).
IT 36768-90-8P 36768-91-9P 36768-92-0P
36768-93-1P 36768-94-2P 36768-95-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 36768-90-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(trifluoromethyl)phenoxy]-, hydrochloride, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 36768-91-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(trifluoromethyl)phenoxy]-, endo- (9CI)

(CA INDEX NAME)

Relative stereochemistry.



RN 36768-92-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(trifluoromethyl)phenoxy]-, hydrochloride, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 36768-93-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[3-(trifluoromethyl)phenoxy]-, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 36768-94-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[4-(trifluoromethyl)phenoxy]-, hydrochloride, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 36768-95-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(2-bromophenoxy)-, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:140921 CAPLUS
DOCUMENT NUMBER: 76:140921
ORIGINAL REFERENCE NO.: 76:22891a,22894a
TITLE: 11-(3α-Nortropanyloxy)-6, 11-dihydrodibenzo[b,e]thiepines and their S-oxides
INVENTOR(S): Gadient, Fulvio
PATENT ASSIGNEE(S): Sandoz Ltd.
SOURCE: Ger. Offen., 18 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2134820	A	19720120	DE 1971-2134820	19710713
CH 528538	A	19720930	CH 1970-528538	19700715
CH 529783	A	19721031	CH 1970-529783	19700715
CH 529784	A	19721031	CH 1970-529784	19700715
CH 529785	A	19721031	CH 1970-529785	19700715
NL 7109301	A	19720118	NL 1971-9301	19710706
BE 769968	A1	19720113	BE 1971-105886	19710713
FR 2100908	A5	19720324	FR 1971-25570	19710713
FR 2100908	B1	19750207		
AU 7131165	A	19730118	AU 1971-31165	19710713
US 3716544	A	19730213	US 1971-162290	19710713
HU 163777	B	19731027	HU 1971-SA2220	19710713
GB 1354538	A	19740530	GB 1971-32851	19710713
ES 393219	A1	19740916	ES 1971-393219	19710713
SE 368955	B	19740729	SE 1971-9119	19710714
AT 7106127	A	19750915	AT 1971-6127	19710714

PRIORITY APPLN. INFO.:

CH 1970-10735	A	19700715
CH 1970-10736	A	19700715
CH 1970-10737	A	19700715
CH 1970-10738	A	19700715

GI For diagram(s), see printed CA Issue.
AB The title compds. (I; n = 0, 1, or 2; R = H, Et, Pr, iso-Pr, or Bu), useful as antiulcerous drugs, were prepared by reaction of II with HX optionally followed by S-oxidation with H2O2. Thus, HCl(g) was passed into III (n = 0) in C6H6 with cooling, crude II (n = 0) obtained was added to boiling HX (R = Et) in xylene, and the mixture refluxed 1 hr to give oily I (n = 0, R = Et) (IV) isolated as methanesulfonate. Treating IV in AcOH with H2O2 for 17 hr at room temperature or 7 hr at 80° yielded I (n = 1, R = Et) and I (n = 2, R = Et), resp. Similarly prepared were 11 other I.
IT 36079-40-0P 36079-41-1P 36079-42-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 36079-40-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6,11-dihydro-5-oxidodibenzo[b,e]thiepin-11-yl)oxy]-, endo-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 47435-95-0
CMF C21 H23 N O2 S

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 36079-41-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6,11-dihydro-5,5-dioxidodibenzo[b,e]thiepin-11-yl)oxy]-, endo-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 47482-42-8
CMF C21 H23 N O3 S

Relative stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 36079-42-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(6,11-dihydrodibenzo[b,e]thiepin-11-yl)oxy]- (CA INDEX NAME)



L4 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1971:62936 CAPLUS
DOCUMENT NUMBER: 74:62936
ORIGINAL REFERENCE NO.: 74:10157a,10160a
TITLE: Comparison of the pharmacological properties of deptropine, its methobromide (BS 7020a) and the 10,11-dehydro analogs
AUTHOR(S): Timmerman, H.; Lavy, U. I.; Mulder, Dirk
CORPORATE SOURCE: Res. Dep., N. V. Koninklijke Pharm. Fabr., Amsterdam, Neth.
SOURCE: Archives Internationales de Pharmacodynamie et de Therapie (1970), 187(2), 291-300
CODEN: AIPTAK; ISSN: 0003-9780
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The antihistaminic and anticholinergic activities of deptropine (3α-[(10,11-dihydro-5H-dibenzo[α,d]cyclohepten-5-yl)oxy]tropane citrate) (I) and its 10,11-dehydro analog, 3α-[(5H-dibenzo[α,d]cyclohepten-5-yl)oxy]tropane maleate (II maleate) were compared in vivo and in vitro in guinea pigs with those of their resp. quaternary methobromide derivs., III and IV. Quaternization enhanced the anticholinergic activities in vitro and in vivo, except on oral administration, probably due to the low absorption of III and IV. The central anticholinergic activity of III and IV was very weak. Little difference was observed between the antihistaminic activities of these 4 compds. Investigations into the effect of these compds. on the refractory period of the isolated guinea pig heart demonstrated a correlation between the lengthening of that parameter and the level of antihistaminic activity. In this regard, III and IV were much less active than I and II maleate, possibly because III and IV failed to reach the site of action.

IT 31420-72-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmacology of)
RN 31420-72-1 CAPLUS
CN 1αH,5αH-Nortropane, 3α-(5H-dibenzo[a,d]cyclohepten-5-yloxy)-, maleate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 47337-72-4
CMF C22 H23 N O

Relative stereochemistry.



CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



L4 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1967:74665 CAPLUS
DOCUMENT NUMBER: 66:74665
ORIGINAL REFERENCE NO.: 66:13979a,13982a
TITLE: Effect of alkyl substitution in drugs. XVI. Basic ethers of 10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ol and some related compounds
AUTHOR(S): Van der Stelt, Cornelius; Funcke, A. B. H.; Tersteege, H. M.; Nauta, Wijbe T.
CORPORATE SOURCE: N. V. Koninkl. Pharmaceut. Fabrieken, Amsterdam, Neth.
SOURCE: Arzneimittel-Forschung (1966), 16(10), 1342-5
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB cf. CA 66, 46310s. Twenty-one basic dibenzocycloheptene ethers and 19 cyclooctene ethers were synthesized and were tested for spasmolytic activities on isolated guinea pig ileum, for antiasthmatic activity in guinea pigs, for antiulcerogenic effect in Shay rats, and for stimulating effects on the central nervous system in mice and guinea pigs. The tropine ethers had the greatest spasmolytic activities. Quaternization afforded substances which were even more effective against acetylcholine but their antihistaminic and central activities were reduced or were completely absent. Detropene citrate was the most effective derivative against bronchoconstriction in guinea pigs. Tropine ethers with the basic structure I and R1 = H and R2 = tropan-3α-yl with MeBr and R1 = 3-Me and R2 = tropan-3α-yl with maleic acid, and the tropine ethers with the basic structure II and R1 = H and R2 = tropan-3α-yl with maleic acid and R1 = 3-Me and R2 = tropan-3α-yl with maleic acid, protected Shay rats against exptl.-induced gastric ulcers. Basic structure I with R1 = H and R2 = 2-(dimethylamino)ethyl with maleic acid, or R1 = H and R2 = 1-methyl-4-piperidyl with maleic acid, stimulated the central nervous system. No general trends regarding the effect of substitution on activity by these compds. was observed. However, derivs. carrying a tert-Bu group or halogen in the 3-position had little activity, and activity was decreased when the substituent on the N atom of the nortropyl residue was larger than Et.
IT 2189-52-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and biol. activity)
RN 2189-52-8 CAPLUS
CN 1αH,5αH-Nortropane, 3α-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]-, maleate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 47337-71-3
CMF C22 H25 N O

Relative stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L4 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1965:462988 CAPLUS
DOCUMENT NUMBER: 63:62988
ORIGINAL REFERENCE NO.: 63:11522f-h
TITLE: 3-(Dibenzo[a,d]-1,4-cycloheptadien-5-yloxy)nortropane
PATENT ASSIGNEE(S): N. V. Koninklijke Pharmaceutische Fabrieken voorheen Brocades-Stheeman & Pharmacia
SOURCE: 9 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 643795		19640814	BE	
PRIORITY APPLN. INFO.:			GB	19630215

GI For diagram(s), see printed CA Issue.

AB The title compound (I) exhibits spasmolytic activity but with less side-effects than the corresponding N-Me derivative (II, R = Me) (Belg. 589,192). I can also be used as intermediate for other therapeutically active agents, e.g. N-alkylated compds. The preparation is given. Thus, a mixture of 6 g. nortropine, 23.6 g. dibenzo[a,d]-1,4-cycloheptadien-5-yl chloride and 8.9 g. NBu3 in 175 ml. PhMe was refluxed 6 hrs.; on addition of 250 ml. acetone and 300 ml. petr. ether (b. 28-40°) 7.6 g. crude HCl salt of I was precipitated, m. 192-4° (PrOH). Further, a solution of II (R = Me) (no weight given) in 100 ml. anhydrous C6H6 was added dropwise to a solution of 11.66 g. BrCN in 100 ml. C6H6; the mixture was refluxed 3 hrs., H2O added, the organic layer separated, dried and evaporated to yield an oil which on addition of EtOH gave 12.5 g. II (R = CN) (IV), m. 158-60° (EtOH). A solution of 9.7 g. IV, 24.0 g. KOH in 12 ml. H2O, and 48 ml. EtOH was refluxed 20 hrs. to yield after the usual workup 11.3 g. I maleate, m. 184.5-86° (EtOH). The preparation of some pharmaceutical forms is given.

IT 2189-52-8
(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 2189-52-8 CAPLUS
CN 1αH,5αH-Nortropane, 3α-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]-, maleate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 47337-71-3
CMF C22 H25 N O

Relative stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



IT 1956-58-7P, Nortropane, 3-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]-, hydrochloride 2183-57-5P, Nortropane, 3-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]- 102346-52-1P, Nortropane, 3-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]-, maleate (1:1)
RL: PREP (Preparation)
(preparation of)

RN 1956-58-7 CAPLUS
CN Nortropane, 3-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]-, hydrochloride (7CI, 8CI) (CA INDEX NAME)



● HCl

RN 2183-57-5 CAPLUS
CN Nortropane, 3-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]- (7CI, 8CI) (CA INDEX NAME)



RN 102346-52-1 CAPLUS
CN Nortropane, 3-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]-, maleate (7CI) (CA INDEX NAME)

CM 1

CRN 2183-57-5
CMF C22 H25 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L4 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1965:462987 CAPLUS
DOCUMENT NUMBER: 63:62987
ORIGINAL REFERENCE NO.: 63:11522c-f
TITLE: N,N-Alkyleniminoalkanamidines
INVENTOR(S): Mull, Robert P.
PATENT ASSIGNEE(S): CIBA Corp.
SOURCE: 4 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3189601		19650615	US 1964-336881	19640110

PRIORITY APPLN. INFO.: US 19640110

AB Addition of 50 g.(CH2)6NH to 212 g. CH2:CHCN, followed by 38% PhCH2NMe3+OH-, refluxing 1.5 hrs., stirring overnight, and fractionation gave (CH2)6NCH2CH2CN (I), b14 121-3°, n30D 1.4710. I (30.4 g.), 13.9 g. NH2OH.HCl in 300 ml. anhydrous EtOH, and NaOEt from 4.6 g. Na in 150 ml. anhydrous EtOH refluxed 3 hrs. gave, after 72 hrs. and treatment of oily concentrates in anhydrous EtOH with dry HCl and adding Et2O, (CH2)6NCH2CH2C(NH2):NOH.2HCl (II), m. 183-5° (decomposition) (EtOH). Action of 40% NaOH on II and extraction with CHCl3 gave (CH2)6NCH2CH2C(NH2):NOH (III), m. 80-82° (xylene). Hydrogenation of 18.5 g. III on 5 g. Rh-Al2O3 in 100 ml. anhydrous EtOH, followed by filtration into HBr in EtOH gave (CH2)6NCH2CH2C(NH2):NH.2HBr (IV), m. 164-6° (EtOH-C6H14). By similar methods were obtained (CH2)5NCH2CH2C(NH2):NH.2HBr, m. 169-70° (EtOH-C6H14); (CH2)7NCH2CH2C(NH2):NH.2HBr, m. 176-8° (EtOH-Et2O); and (CH2)6NCH2C(NH2):NH.2HBr, m. 186-8° (C6H14-EtOH). HBr was passed through 15.2 g. I and 7.0 g. EtSH 30 min. to give (CH2)6NCH2CH2C(SEt):NH.2HBr, m. 152-4°, which on treatment with 10% NH3 in anhydrous EtOH gave IV. To a refluxing solution of 52.5 g. (CH2)6NH in 125 ml. C6H6 was added 40 g. Br(CH2)3CN in 60 ml. C6H6 to give, after 5 hrs. refluxing and fractionation, 36.2 g. (CH2)6N(CH2)3CN (V), b15 129-30°. A mixture of 36.2 g. V, 12.66 g. NH2OH.HCl, and 450 ml. EtOH, treated 3 hrs. with 4.22 g. Na in 250 ml. EtOH gave 11.4 g. (CH2)6N(CH2)3C(NH2):NOH, m. 87-9° (C6H14-EtOH), 10 g. of which gave 7 g. (CH2)6N(CH2) 3C(NH2):NH.2HBr, m. 142-4° (C6H14-EtOH). These amidines and their dihydrobromides can be used as antihypertensive agents.

IT 2189-52-8
(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 2189-52-8 CAPLUS

CN 1αH,5αH-Nortropane, 3α-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]-, maleate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 47337-71-3
CMF C22 H25 N O

Relative stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L4 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1965:22721 CAPLUS
DOCUMENT NUMBER: 62:22721
ORIGINAL REFERENCE NO.: 62:4074d-f
TITLE: 3-(Dibenzo[a,d]-1,4-cycloheptadien-5-yloxy)nortropane and its non-toxic salts
PATENT ASSIGNEE(S): N. V. Koninklijke Pharmaceutische Fabrieken voorheen Brocades-Stheeman & Pharmacia
SOURCE: 7 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 6401268		19640817	NL 1964-1268	19640213
PRIORITY APPLN. INFO.:			GB	19630215

GI For diagram(s), see printed CA Issue.

AB The title compound (I) had spasmolytic action [as did its N-Me derivative (II), Belg. 589,192], but was superior to II as to side effects. A mixture of 6 g. nortropine, 23.6 g. dibenzo[a,d]-1,4-cycloheptadien-5-yl chloride, and 8.9 g. Bu3N in 175 cc. dry toluene refluxed 6 hrs., the solvent distilled in vacuo, and a mixture of 250 cc. Me2CO and 300 cc. petr.-ether (b. 28-40°) added gave 7.6 g. I.HCl, m. 192-4° (PrOH). II and BrCN in C6H6 gave the N-CN derivative of I, m. 158-60° (EtOH), which with KOH gave I, isolated as its maleate, m. 184.5-6° (EtOH). A pharmaceutical composition containing the citrate of I is given.

IT 2183-57-5, Nortropane, 3-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]-
(derivs.)
RN 2183-57-5 CAPLUS
CN Nortropane, 3-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]- (7CI, 8CI) (CA INDEX NAME)



IT 1956-58-7P, Nortropane, 3-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]-, hydrochloride 2183-57-5P, Nortropane, 3-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]- 102346-52-1P, Nortropane, 3-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]-, maleate (1:1)
RL: PREP (Preparation)
(preparation of)
RN 1956-58-7 CAPLUS
CN Nortropane, 3-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]-, hydrochloride (7CI, 8CI) (CA INDEX NAME)



● HCl

RN 2183-57-5 CAPLUS
CN Nortropane, 3-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]- (7CI, 8CI) (CA INDEX NAME)



RN 102346-52-1 CAPLUS
CN Nortropane, 3-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)oxy]-, maleate (7CI) (CA INDEX NAME)

CM 1

CRN 2183-57-5
CMF C22 H25 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



```
=> d his

     (FILE 'HOME' ENTERED AT 12:26:01 ON 02 MAR 2008)

     FILE 'REGISTRY' ENTERED AT 12:26:27 ON 02 MAR 2008
L1             STRUCTURE UPLOADED
L2              10 S L1
L3             278 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 12:26:52 ON 02 MAR 2008
L4              28 S L3 FULL
```